ベーチェット病診療ガイドライン　2020

書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,280 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

ベーチェット病標準化医療のバイブルがついに完成！ベーチェット病は，全身に多様な症状が出現する難治性炎症性疾患で，特異的な検査所見がないために診断に苦慮することも少なくありません．本書では多臓器にわたる症状を横断的に理解できるよう，治療に限らず症状や所見に関するアルゴリズム・CQを豊富に収録し，ベーチェット病の多彩な症状・所見・治療すべてを網羅．ベーチェット病専門外の一般医にも使いやすい1冊です．

目次

  • 第1章　ガイドライン作成にあたって

    第2章　ベーチェット病の疾患概念，病因・病態
    　［1］疾患概念
    　［2］病因・病態

    第3章　ベーチェット病の臨床
    　［1］症状，身体所見
    　(1)主症状
    　　(a)口腔内アフタ性潰瘍
    　　(b)皮膚症状
    　　(c)眼症状
    　　(d)外陰部潰瘍
    　(2)副症状
    　　(a)関節炎
    　　(b)精巣上体炎（副睾丸炎）
    　　(c)消化器病変（腸管型ベーチェット病）
    　　(d)血管病変（血管型ベーチェット病）
    　　(e)中枢神経病変（神経型ベーチェット病）
    　［2］血液生化学検査所見
    　［3］厚生労働省ベーチェット病診断基準（2016年小改訂）
    　［4］ベーチェット病重症度分類（2016年小改訂）
    　［5］疫学（症状，重症度の変遷）
    　［6］ベーチェット病患者の妊娠について
    　［7］小児ベーチェット病の特徴

    第4章　ベーチェット病の診療ガイドライン
    　［1］診断・治療に関するアルゴリズム
    　(1)皮膚粘膜病変治療アルゴリズム
    　(2)眼病変治療アルゴリズム
    　(3)関節病変治療アルゴリズム
    　(4)精巣上体炎診断治療アルゴリズム
    　(5)腸管型ベーチェット病診断治療アルゴリズム
    　(6)血管型ベーチェット病診断治療アルゴリズム
    　(7)神経型ベーチェット病診断治療アルゴリズム
    　［2］診断・治療のクリニカルクエスチョン（CQ）と推奨文，推奨度，解説
    　(1)皮膚粘膜病変CQ
    　　(a)口腔内アフタ性潰瘍
    　　(b)外陰部潰瘍
    　　(c)結節性紅斑
    　　(d)毛包炎様皮疹
    　　(e)血栓性静脈炎
    　(2)眼病変CQ
    　　(a)眼発作時の治療
    　　(b)眼発作抑制の治療（TNF 阻害薬以外の治療）
    　　(c)TNF阻害薬
    　　(d)眼科手術
    　(3)関節病変CQ
    　(4)精巣上体炎CQ
    　(5)腸管病変CQ
    　　(a)診　断
    　　(b)予　後
    　　(c)モニタリングと治療目標
    　　(d)治療（内科的治療）・総論
    　　(e)治療（内科的治療）・各論
    　　(f)治療（外科的治療）
    　　(g)その他（小児例，トリソミー8など）
    　(6)血管病変CQ
    　(7)神経病変CQ
    　　(a)神経型ベーチェット病の一般的事項
    　　(b)急性型神経型ベーチェット病について
    　　(c)慢性進行型神経型ベーチェット病について
    　(8)小児ベーチェット病CQ
    　(9)治療総論CQ
    　　(a)TNF阻害薬に関する注意点
    　　(b)妊娠・授乳中の薬物治療リスク

    第5章　参考資料・情報
    　［1］ベーチェット病国際診断基準（ISG, ICBD, PEDBDなど）との比較
    　［2］神経型ベーチェット病メタ解析
    　［3］ベーチェット病臨床調査個人票（2016年改訂）
    　［4］関連情報
    　［5］ベーチェット病患者会情報
    　［6］ベーチェット病に関する調査研究班のあゆみ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 ガイドライン作成にあたって

P.5 掲載の参考文献
1. 福井次矢, 他 (編) : Minds診療ガイドライン作成の手引き 2007. 医学書院, 2007.
 
2. 福井次矢, 他 (編) : Minds診療ガイドライン作成の手引き 2014. 医学書院, 2014.
 

第2章 ベーチェット病の疾患概念, 病因・病態

P.11 掲載の参考文献
1. Behcet H : Uber rezidivierende, aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937 ; 105 : 1152-1157.
 
2. 黒澤潤三 : 再発性蓄膿性虹彩毛様体炎ノ一例. 中央眼科医報 1923 ; 15 : 653-656.
 
3. 重田達夫 : 前房蓄膿ヲ伴フ再発性虹彩炎ニ就テ及ソノ病理解剖. 日眼会誌 1924 ; 28 : 516-528.
 
4. Adamantiades B : A case of relapsing iritis with hypopyon (in Greek). Archia Iatrikis Etairias (Proceedings of the Medical Society of Athens). 1930 : 586-593.
 
5. Adamantiades B : Sur un cas d'iritis a hypopion recidivant. Ann Ocul (Paris) 1931 ; 168 : 271-278.
 
6. Ohno S, et al. : HL-A5 and Behcet's disease. Lancet 1973 ; 2 : 1383-1384.
PubMed
7. Ohno S, et al. : HLA-BW51 and Behcet's disease. JAMA 1978 ; 240 : 529.
PubMed
8. Mizuki N, et al. : Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010 ; 42 : 703-706.
PubMed
9. Kirino Y, et al. : Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013 ; 45 : 202-207.
PubMed
10. 大野重昭 : 眼疾患発症の外因と内因. 日眼会誌 2005 ; 109 : 885-915.
 
11. Ohno S, et al. : Close Association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982 ; 100 : 1455-1458.
PubMed
12. Verity DH, et al. : Behcet's disease, the Silk Road and HLA-B51 : historical and geographical perspectives. Tissue Antigens 1999 ; 54 : 213-220.
PubMed
13. 大野重昭, 他 : ベーチェット病の診療の歴史・疫学・疾患概論. 飯塚文瑛, 他 (編) : 腸管ベーチェット病のすべてがわかる診療ハンドブック. 先端医学社, 2018 : 2-11.
 
P.17 掲載の参考文献
1. Mizuki N, et al. : Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010 ; 42 : 703-706.
PubMed
2. Remmers EF, et al. : Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010 ; 42 : 698-702.
PubMed
3. Kirino Y, et al. : Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013 ; 45 : 202-207.
PubMed
4. KirinoY, et al. : Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci USA 2013 ; 110 : 8134-8139.
PubMed
5. Miossec P, et al. : Interleukin-17 and type 17 helper T cells. N Engl J Med 2009 ; 361 : 888-898.
PubMed
6. Leng RX, et al. : The role of IL23/IL17 axis in the etiopathogenesis of Behcet's disease. Clin Rheumatol 2010 ; 29 : 1209.
 
7. Arayssi T, et al. : New insights into the pathogenesis and therapy of Behcet's disease. Curr Opin Pharmacol 2004 ; 4 : 183-188.
PubMed
8. Lasiglie D, et al. : Role of IL-1 beta in the development of human T (H) 17 cells : lesson from NLPR3 mutated patients. PLoS One 2011 ; 6 : e20014.
 
9. Yasuoka H, et al. : Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behcet's disease. Arthritis Rheum 2004 ; 50 : 3658-3662.
 
10. Kastner DL, et al. : Autoinflammatory disease reloaded : a clinical perspective. Cell 2010 ; 140 : 784-790.
PubMed
11. Gul A : Behcet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005 ; 4 : 81-85.
PubMed
12. McGonagle D, et al. : A proposed classification of the immunological disease. PLoS Med 2006 ; 3 : e297.
PubMed
13. Takeuchi M, et al. : Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet's disease susceptibility. Nat Genet 2017 ; 49 : 438-443.
PubMed
14. Masters SL, et al. : Horror autoinflammaticus : the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009 ; 27 : 621-668.
PubMed

第3章 ベーチェット病の臨床

P.21 掲載の参考文献
1. 中村晃一郎, 他 : ベーチェット病の皮膚粘膜病変診療ガイドライン. 日皮会誌 2018 ; 128 : 2087-2101.
 
P.23 掲載の参考文献
1. 中村晃一郎, 他 : ベーチェット病の皮膚粘膜病変診療ガイドライン. 日皮会誌 2018 ; 128 : 2087-2101.
 
P.25 掲載の参考文献
1. ベーチェット病眼病変診療ガイドライン作成委員会 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
P.26 掲載の参考文献
1. 中村晃一郎, 他 : ベーチェット病の皮膚粘膜病変診療ガイドライン. 日皮会誌 2018 ; 128 : 2087-2101.
 
P.29 掲載の参考文献
1. Hirohata S, et al. : Behcet's disease. Arthritis Res Ther 2003 ; 5 : 139-146.
PubMed
2. Kirkali Z, et al. : Urological aspects of Behcet's disease. Br J Urol 1991 ; 67 : 638-639.
PubMed
3. Pannek J, et al. : Orchitis due to vasculitis in autoimmune diseases. Scand J Rheumatol 1997 ; 26 : 151-154.
PubMed
4. Sharquie KE, et al. : Epididymo-orchitis in Behcets disease. Br J Rheumatol 1987 ; 26 : 468-469.
PubMed
5. 桑名正隆, 他 : ベーチェット病における精巣特異抗原に対する自己抗体. 厚生科学研究特定疾患対策研究事業 ベーチェット病に関する研究 平成11年度報告書 (主任研究者 ; 大野重昭). 2000 : 65-73.
 
6. Cho YH, et al. : Clinical features of patients with Behcet's disease and epididymitis. J Urol 2003 ; 170 : 1231-1233.
PubMed
7. 堀井沙也佳, 他 : 両側精巣上体炎から不全型ベーチェット病と診断された1例. 泌尿器科紀要 2014 ; 60 : 593-596.
 
8. Cetinel B, et al. : Urologic screening for men with Behcet's syndrome. Urology 1998 ; 52 : 863-865.
PubMed
9. Davatchi F, et al. : Adult Behcet's disease in Iran : analysis of 6075 patients. Int J Rheum Dis 2016 ; 19 : 95-103.
 
10. 黒沢美智子, 他 : ベーチェット病診療ガイドライン作成に向けて, 臨床調査個人票新規申請データで患者の実態を示す. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) ベーチェット病に関する調査研究 平成27年度総括・分担研究報告書 (研究代表者 ; 水木信久). 2016 : 52-58.
 
11. Ideguchi H, et al. : Behcet disease : evolution of clinical manifestations. Medicine (Baltimore) 2011 ; 90 : 125-132.
PubMed
12. 中江公裕, 他 : ベーチェット病患者全国疫学調査成績 : 臨床疫学的成績とHLA-B51 との関連. 厚生省特定疾患ベーチェット病調査研究班 平成4年度研究業績 (班長 ; 坂根剛). 1993 : 70-82.
 
13. Kaklamani VG, et al. : Recurrent epididymo-orchitis in patients with Behcet's disease. J Urol 2000 ; 163 : 487-489.
PubMed
14. Callejas-Rubio JL, et al. : Recurrent epididymo-orchitis secondary to Behcets disease. J Urol 1998 ; 160 : 496.
PubMed
15. Kenneth T C, et al. : Miscellaneous Manifestations of Behcet's Disease. In : Yazici Y, et al. (eds) : Behcet's Syndrome. Springer Science+Business Media, 2010 : 189-204.
 
16. 黒沢美智子, 他 : 臨床調査個人票を用いたベーチェット病の予後の研究方法 新規受給者の1年後, 5年後の予後と1年後の予後に関連する要因. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23～25年度総合研究報告書 (研究代表者 ; 石ヶ坪良明). 2014 : 93-98.
 
P.31 掲載の参考文献
1. 久松理一 : 腸管Behcet病. 診断と治療 2017 ; 105 (Suppl.) : 169-173.
 
2. 石ヶ坪良明 : 腸管ベーチェット病診療ガイドライン平成21年度案-コンセンサス・ステートメントに基づく-. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成20～22年度総合研究報告書 (研究代表者 ; 石ヶ坪良明). 2010 : 230-234.
 
3. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of Intestinal Behcet's Disease-Indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
 
4. 武藤徹一郎 : いわゆる "simple ulcer" とは. 胃と腸 1979 ; 14 : 739-748.
 
5. 渡辺英伸, 他 : 回盲弁近傍の単純性潰瘍の病理. 胃と腸 1979 ; 14 : 749-767.
 
6. Jung YS, et al. : Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
7. Jung YS, et al. : Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 1594-1602.
PubMed
8. Kobayashi K, et al. : Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol 2007 ; 42 : 737-745.
PubMed
9. Tanida S, et al. : Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015 ; 13 : 940-948.
PubMed
10. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863
 
P.33 掲載の参考文献
1. Takeno M, et al. : Vascular involvement of Behcet's disease. In : Ishigatsubo Y (eds) : Behcet's disease. Springer Japan, 2015 : 79-100.
 
2. Ideguchi H, et al. : Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 2011 ; 29 : S47-53.
PubMed
3. 石ヶ坪良明, 他 : 血管ベーチェット病の臨床像 : ベーチェット病研究班内調査-全国疫学調査と自験例との比較. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2012 : 76-82.
 
4. Tascilar K, et al. : Vascular involvement in Behcet's syndrome : a retrospective analysis of associations and the time course. Rheumatology (Oxford) 2014 ; 53 : 2018-2022.
PubMed
5. Saadoun D, et al. : Mortality in Behcet's disease. Arthritis Rheum 2010 ; 62 : 2806-2812.
PubMed
6. Seyahi E, et al. : Pulmonary artery involvement and associated lung disease in Behcet disease : a series of 47 patients. Medicine (Baltimore) 2012 ; 91 : 35-48.
PubMed
7. Kobayashi M, et al. : Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 2000 ; 36 : 362-371.
PubMed
8. Seyahi E, et al. : An outcome survey of 43 patients with Budd-Chiari syndrome due to Behcet's syndrome followed up at a single, dedicated center. Semin Arthritis Rheum 2015 ; 44 : 602-609.
 
9. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
10. Saadoun D, et al. : Long-term outcome of arterial lesions in Behcet disease : a series of 101 patients. Medicine (Baltimore) 2012 ; 91 : 18-24.
PubMed
11. Tuzun H, et al. : Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. J Vasc Surg 2012 ; 55 : 157-163.
PubMed
12. Kingston M, et al. : Aneurysm after arterial puncture in Behcet's disease. Br Med J 1979 ; 1766-1767.
PubMed
13. Lakhanpal S, et al. : Pathologic features of Behcet's syndrome : a review of Japanese autopsy registry data. Hum Pathol 1985 ; 16 : 790-795.
PubMed
14. Geri G, et al. : Spectrum of cardiac lesions in Behcet disease : a series of 52 patients and review of the literature. Medicine (Baltimore) 2012 ; 91 : 25-34.
PubMed
15. Soussan M, et al. : Management of large-vessel vasculitis with FDG-PET : a systematic literature review and meta-analysis. Medicine (Baltimore) 2015 ; 94 : e622.
PubMed
16. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
17. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
18. Hatemi G, et al. : Management of Behcet disease : a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009 ; 68 : 1528-1534.
PubMed
19. Mehta P, et al. : Thrombosis and Behcet's syndrome in non-endemic regions. Rheumatology (Oxford) 2010 ; 49 : 2003-2004.
PubMed
20. Ha YJ, et al. : Long-term clinical outcomes and risk factors for the occurrence of post-operative complications after cardiovascular surgery in patients with Behcet's disease. Clin Exp Rheumatol 2012 ; 30 : S18-26.
PubMed
21. Hosaka A, et al. : Prognosis of arterial aneurysm after surgery in patients with Behcet's disease. Int Angiol 2014 ; 33 : 419-425.
PubMed
P.37 掲載の参考文献
1. 広畑俊成 : 神経ベーチェット病の病態. 臨床神経 2001 ; 41 : 1147-1149.
 
2. Akman-Demir G, et al. : Clinical patterns of neurological involvement in Behcet's disease : evaluation of 200 patients. Brain 1999 ; 122 : 2171-2182.
PubMed
3. Hirohata S, et al. : Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997 ; 82 : 12-17.
PubMed
4. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
5. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
6. Kikuchi H, et al. : Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behcet's disease. J Neurol Sci 2014 ; 337 : 80-85.
PubMed
7. 廣畑俊成, 他 : 神経ベーチェット病の診療のガイドライン. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23～25年度総合研究報告書 (研究代表者 ; 石ヶ坪良明). 2014 : 247-252.
 
8. Hirohata S, et al. : Low dose weekly methotrexate therapy for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998 ; 159 : 181-185.
PubMed
9. Hirohata S, et al. : Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 2015 ; 349 : 143-148.
PubMed
10. Kikuchi H, et al. : Effect of infliximab in progressive Neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
P.38 掲載の参考文献
1. 日本ベーチェット病学会 : ベーチェット病の診断基準 (2016年小改訂). 2016. http://www-user.yokohama-cu.ac.jp/~jbehcet/jigyou/shindan.html (アクセス日 : 2019年10月23日)
 
2. Lehner T, et al. : Recent advances in T-cell immunoregulation and in the microbial causes of Behcet's disease. In : O' Duffy J et al. (eds) : Behcet's disease-Basic and Clinical Aspects. Marcel Dekker, 1991 : 475-485.
 
3. Ohno S, et al. : Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982 ; 100 : 1455-1458.
PubMed
4. Mizuki N, et al. : A strong association between HLA-B*5101 and Behcet's disease in Greek patients. Tissue Antigens 1997 ; 50 : 57-60.
 
5. Mizuki N, et al. : Triplet repeat polymorphism in the transmembrane region of the MICA gene : a strong association of six GCT repetitions with Behcet disease. Proc Natl Acad Sci U S A 1997 ; 94 : 1298-1303.
PubMed
6. 目黒明, 他 : HLAとBehcet's病. あたらしい眼科 2006 ; 23 : 1521-1527.
 
7. Mizuki N, et al. : Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010 ; 42 : 703-706.
PubMed
8. Kirino T, et al. : Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013 ; 45 : 202-207.
 
9. Kirino T, et al. : Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci U S A 2013 ; 110 : 8134-8139.
 
P.46 掲載の参考文献
1. 清水保, 他 : 厚生省特定疾患ベーチェット病調査研究班. ベーチェット病患者全国疫学調査成績. 1974.
 
2. 黒沢美智子, 他 : Behcet病の最近の疫学像の動向. 医学のあゆみ 2005 ; 215 : 5-8.
Medical*Online
3. 大野良之, 他 : ベーチェット病. 難病の最新情報-疫学から臨床・ケアまで. 南山堂, 2000 : 106-110.
 
4. 稲葉裕 : ベーチェット病全国疫学調査-臨床疫学像. 厚生労働科学研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成16年度総括・分担研究報告書 (主任研究者 ; 金子史男). 2005 : 91-94.
 
5. 中江公裕 : 最近のベーチェット病の疫学. 日本医事新報 1995 ; 3717 : 124-126.
Medical*Online
6. 中江公裕 : ベーチェット病患者全国疫学調査成績. 厚生省特定疾患ベーチェット病調査研究班 平成4年度研究業績 (班長 ; 坂根剛). 1993 : 40-82.
 
7. 中江公裕 : ベーチェット病. 日本疫学会 (編) : 疫学ハンドブック-重要疾患の疫学と予防. 南山堂, 1998 : 256-259.
 
8. 厚生労働省 : 衛生行政報告例 : 結果の概要. https://www.mhlw.go.jp/toukei/list/36-19a.html (アクセス日 : 2019年8月22日)
 
9. 難病情報センター : 特定疾患医療受給者証所持者数. http://www.nanbyou.or.jp/entry/1356 (アクセス日 : 2019年8月22日)
 
10. 永井正規, 他 : 特定疾患治療研究医療受給者調査報告書 (1992年度分) その1 基本的集計. 厚生省特定疾患難病の疫学班調査研究班. 1995.
 
11. 黒澤美智子 : 日本におけるベーチェット病の臨床疫学像. リウマチ科 2015 ; 53 : 537-542.
 
12. Khairallah M, et al. : Epidemiology of Behcet's disease. Ocul immunol inflam 2012 ; 20 : 324-335.
 
P.48 掲載の参考文献
1. Ishido T, et al. : Clinical manifestations of Behcet's disease depending on sex and age : results from Japanese nationwide registration. Rheumatology (Oxford) 2017 ; 56 : 1918-1927.
PubMed
2. Kirino Y, et al. : Continuous evolution of clinical phenotype in 578 Japanese patients with Behcet's disease : a retrospective observational study. Arthritis Res Ther 2016 ; 18 : 217.
PubMed
3. 岳野光洋 : ベーチェット病と妊娠. リウマチ科 2014 ; 52 : 69-75.
 
4. Gatto M, et al. : Pregnancy and vasculitis : a systematic review of the literature. Autoimmun Rev 2012 ; 11 : A447-459.
PubMed
5. Erlebacher A : Immunology of the maternal-fetal interface. Annu Rev Immunol 2013 ; 31 : 387-411.
PubMed
6. Battinelli EM, et al. : The role of thrombophilia in pregnancy. Thrombosis 2013 ; 2013 : 516420.
PubMed
7. Carvalheiras G, et al. : Fetal outcome in autoimmune diseases. Autoimmun Rev 2012 ; 11 : A520-530.
PubMed
8. Hamza M, et al. : Behcet's disease and pregnancy. Ann Rheum Dis 1988 ; 47 : 350.
PubMed
9. Bang D, et al. : The influence of pregnancy on Behcet's disease. Yonsei Med J 1997 ; 38 : 437-443.
PubMed
10. Marsal S, et al. : Behcet's disease and pregnancy relationship study. Br J Rheumatol 1997 ; 36 : 234-238.
PubMed
11. Gul U : Pregnancy and Behcet disease. Arch Dermatol 2000 ; 136 : 1063-1064.
PubMed
12. Uzun S, et al. : The clinical course of Behcet's disease in pregnancy : a retrospective analysis and review of the literature. J Dermatol 2003 ; 30 : 499-502.
PubMed
13. Jadaon J, et al. : Behcet's disease and pregnancy. Acta Obstet Gynecol Scand 2005 ; 84 : 939-944.
PubMed
14. Noel N, et al. : Behcet's disease and pregnancy. Arthritis Rheum 2013 ; 65 : 2450-2456.
PubMed
15. Iskender C, et al. : Behcet's disease and pregnancy : a retrospective analysis of course of disease and pregnancy outcome. J Obstet Gynaecol Res 2014 ; 40 : 1598-1602.
PubMed
16. Hwang I, et al. : Necrotizing villitis and decidual vasculitis in the placentas of mothers with Behcet disease. Hum Pathol 2009 ; 40 : 135-138.
PubMed
17. Hiwarkar P, et al. : Deep vein and intracardiac thrombosis during the post-partum period in Behcet's disease. Int J Hematol 2010 ; 91 : 679-686.
PubMed
18. Komaba H, et al. : Extensive deep vein thrombosis in a postpartumwoman with Behcet's disease associated with nephrotic syndrome. Kidney Int 2007 ; 71 : 6.
 
19. Wechsler B, et al. : Pregnancy complicated by cerebral venous thrombosis in Behcet's disease. Am J Obstet Gynecol 1995 ; 173 : 1627-1629.
PubMed
20. Takeno M, et al. : Vascular involvement of Behcet's disease. In : Ishigatsubo Y (eds) : Behcet's disease. Springer Japan, Tokyo, 2015 : 79-100.
 
P.51 掲載の参考文献
1. Ozen S : Behcet Disease. In : Petty RE, et al. (eds) : Textbook of Pediatric Rheumatology, 7th ed, Saunders, Philadelphia, 2016 ; 526-532 : e2.
 
2. 山口賢一, 他 : 小児Behcet病. 別冊日本臨床 2015 ; 34 : 867-873.
 
3. 藤川敏 : 小児期発症ベーチェット病. 日児誌 2004 ; 108 : 359-367.
 
4. 難病情報センター : ベーチェット病 (平成27年5月10日改訂版). http://www.nanbyou.or.jp/entry/187. (アクセス日 : 2018年12月31日)
 
5. Kone-Paut I, et al. : Consensus classification criteria for paediatric Behcet's disease from a prospective observational cohort : PEDBD. Ann Rheum Dis 2016 ; 75 : 958-964.
PubMed

第4章 ベーチェット病の診療ガイドライン

P.62 掲載の参考文献
1. Taylor J, et al. : Interventions for the management of oral ulcers in Behcet's disease. Cochrane Database Syst Rev 2014 ; 25 : CD011018.
 
2. Mangelsdorf HC, et al. : Behcet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol 1996 ; 34 : 745-750.
PubMed
P.63 掲載の参考文献
1. Davatchi F, et al. : Colchicine versus placebo in Behcet's disease : randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009 ; 19 : 542-549.
 
1. Taylor J, et al. : Interventions for the management of oral ulcers in Behcet's disease. Cochrane Database Syst Rev 2014 ; 25 : CD011018.
 
2. Mat C, et al. : A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 2006 ; 45 : 348-352.
PubMed
2. Yurdakul S, et al. : A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-2692.
PubMed
3. Verma KK, et al. : Severe mucocutaneous Behcet's disease treated with dexamethasone pulse. J Assoc Physicians India2005 ; 53 : 998-999.
PubMed
3. Miyachi Y, et al. : Colchicine in the treatment of the cutanesous manifestations of Behcet's disease. Br J Dermatol 1981 ; 104 : 67-69.
 
P.64 掲載の参考文献
1. Matsuda T, et al. : Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease : a randomised, double-blind, placebo-controlled study. Drugs R D 2003 ; 4 : 19-28.
 
1. Calguneri M, et al. : Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology 1996 ; 192 : 125-128.
PubMed
2. Alpsoy E, et al. : The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease : a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999 ; 135 : 529-532.
PubMed
2. Al-Waiz MM, et al. : Colchicine and benzathine penicillin in the treatment of Behcet disease : a case comparative study. Dermatol Online J 2005 ; 11 : 3.
PubMed
P.65 掲載の参考文献
1. Hatemi G, et al. : Apremilast for Behcet's Syndrome-A phase 2, placebo-controlled Study. N Eng J Med 2015 ; 372 : 1510-1518.
 
1. Melikoglu M, et al. : Short-term trial of etanercept in Behcet's disease : a double blind, placebo controlled study. J Rheumatol 2005 ; 32 : 98-105.
PubMed
2. Hatemi G, et al. : Apremilast for Behcet's syndrome : Abstract from EULAR Annual European Congress of Rheumatology, 2018.
 
2. Almoznino G, et al. : Infliximab for the treatment of resistant oral ulcers in Behcet's disease : a case report and review of the literature. Clin Exp Rheumatol 2007 ; 25 (Suppl 45) : S99-S102.
 
P.66 掲載の参考文献
1. Hatemi G, et al. : EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-1662.
PubMed
1. Hatemi G, et al. : EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-1662.
PubMed
2. Alpsoy E : New Evidence-Based Treatment Approach in Behcet's Disease. Patholog Res Int 2012 ; 2012 : 871019.
PubMed
2. Alpsoy E : New Evidence-Based Treatment Approach in Behcet's Disease. Patholog Res Int 2012 ; 2012 : 871019.
PubMed
3. Mat C, et al. : A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 2006 ; 45 : 348-352.
PubMed
P.67 掲載の参考文献
1. Aktulga E, et al. : A double blind study of colchicine in Behcet's disease. Haematologica 1980 ; 65 : 399-402.
PubMed
1. Chan WP, et al. : Combination therapy with infliximab and methotrexate in recalcitrant mucocutaneous Behcet disease. Cutis 2012 ; 89 : 185-190.
PubMed
2. Kasugai C, et al. : Infliximab treatment of severe genital ulcers associated with Behcet disease. J Am Acad Dermatol 2010 ; 62 : 162-164.
PubMed
2. Yurdakul S, et al. : A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-2692.
PubMed
3. Davatchi F, et al. : Colchicine versus placebo in Behcet's disease : randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009 ; 19 : 542-549.
 
3. Connolly M, et al. : Infliximab treatment for severe orogenital ulceration in Behcet's disease. Br J Dermatol 2005 ; 153 ; 1073-1075.
PubMed
4. Gulli S, et al. : Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy : a case report. BMC Musculoskelet Disord 2003 ; 4 : 19.
 
5. Olivieri I, et al. : Successful treatment of recalcitrant genital ulcers of Behcet's disease with adalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 2009 ; 27 (Suppl 53) : S112.
 
P.68 掲載の参考文献
1. Takeuchi A, et al. : Efficacy of oxaprozin in the treatment of articular symptoms of Behcet's disease. Clin Rheumatol 1984 ; 3 : 397-399.
PubMed
1. Alpsoy E : New Evidence-Based Treatment Approach in Behcet's Disease. Patholog Res Int 2012 ; 2012 : 871019.
PubMed
2. Simsek H, et al. : Treatment of Behcet disease with indomethacin. Int J Dermatol 1991 ; 30 : 54-57.
PubMed
3. Davatchi F, et al. : How to deal with Behcet's disease in daily practice. Int J Rheum Dis 2010 ; 13 : 105-116.
PubMed
P.69 掲載の参考文献
1. Sharquie KE, et al. : Dapsone in Behcet's disease : a double-blind, placebo-controlled, cross-over study. J Dermatol 2002 ; 29 : 267-279.
PubMed
1. Kaneko F, et al. : Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997 ; 38 : 444-454.
PubMed
P.70 掲載の参考文献
1. Mat C, et al. : A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 2006 ; 45 : 348-352.
PubMed
1. Yurdakul S, et al. : A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-2692.
PubMed
2. Davatchi F, et al. : Colchicine versus placebo in Behcet's disease : randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009 ; 19 : 542-549.
 
3. Aktulga E, et al. : A double blind study of colchicine in Behcet's disease. Haematologica 1980 ; 65 : 399-402.
PubMed
P.71 掲載の参考文献
1. Alpsoy E, et al. : A randomized, controlled and blinded study of papulopustular lesion in Turkish Behcet's patient. Int J Dermatol 1998 ; 37 : 839-843.
PubMed
1. Melikoglu M, et al. : Short-term trial of etanercept in Behcet's disease : a double blind, placebo controlled study. J Rheumatol 2005 ; 32 : 98-105.
PubMed
2. Estrach C, et al. : Behcet's syndrome : response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002 ; 41 : 1213-1214.
PubMed
3. Sfikakis PP, et al. : Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007 ; 46 : 736-741.
PubMed
P.72 掲載の参考文献
1. Kawakami T, et al. : Antiphosphatidylserine-prothrombin complex antibodies in 3 patients with Behcet disease involving superficial vein thrombophlebitis. Arch Dermatol 2009 ; 145 : 171-175.
PubMed
1. Davatchi F, et al. : Colchicine versus placebo in Behcet's disease : randomized, double-blind controlled crossover trial. Mod Rheumatol 2009 ; 19 : 542-549.
 
1. Mumcu G, et al. : Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behcet's disease. Int J Dermatol 2013 ; 52 : 1561-1566.
PubMed
2. Kawakami T, et al. : Significance of two skin biopsy performances with consecutive deeper sections in the differential diagnosis between cutaneous polyarteritis nodosa and livedo vasculopathy. Acta Derm Venereol 2014 ; 94 : 84-85.
PubMed
P.73 掲載の参考文献
1. Assaad-Khalil SH : Low-dose cyclosporin in Behcet's diseas : follow-up controlled study with emphasis on extraocular manifestations and neuro-Behcet's disease. In : O' Duffy JD, et al. (eds) : Behcets Disease : Basic and Clinical Aspects. Marcel Dekker, New York, 1991 ; 603-612.
 
2. Cantini F, et al. : Treatment of thrombophlebitis of Behcet's disease with low dose cyclosporin A. Clin Exp Rheumatol 1999 ; 17 : 391-392.
PubMed
3. Wu X, et al. : Behcet's disease complicated with thrombosis : a report of 93 Chinese cases. Medicine (Baltimore) 2014 ; 93 : e263.
PubMed
4. Vikas A, et al. : Behcet's disease with relapsing cutaneous polyarteritis-nodosa-like lesions, responsive to oral cyclosporine therapy. Dermatol Online J 2003 ; 9 : 9.
PubMed
P.74 掲載の参考文献
1. Dogan SM, et al. : Right ventricular thrombus with Behcet's syndrome : successful treatment with warfarin and immunosuppressive agents. Tex Heart Inst J 2007 ; 34 : 360-362.
PubMed
1. Davatchi F, et al. : Colchicine versus placebo in Behcet's disease : randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009 ; 19 : 542-549.
 
2. Yurdakul S, et al. : A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-2692.
PubMed
2. 福本智恵, 他 : 下肢の血栓性静脈炎に対しワルファリンカルシウムが奏効したベーチェット病の1例. 皮膚臨床 1998 ; 40 : 2075-2078.
 
3. Shah B, et al. : Effect of colchicine on platelet-platelet and platelet-leukocyte interactions : a pilot study in healthy subjects. Inflammation 2016 ; 39 : 182-189.
PubMed
3. Kawakami T, et al. : Antiphosphatidylserine-prothrombin complex antibodies in 3 patients with Behcet disease involving superficial vein thrombophlebitis. Arch Dermatol 2009 ; 145 : 171-175.
PubMed
4. Ozen S, et al. : Behcet disease : treatment of vascular involvement in children. Eur J Pediatr 2010 ; 169 : 427-430.
PubMed
P.75 掲載の参考文献
1. Evereklioglu C : Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005 ; 50 : 297-350.
PubMed
1. Evereklioglu C : Ocular Behcet disease : current therapeutic approaches. Curr Opin Ophthalmol 2011 ; 22 : 508-516.
PubMed
2. Evereklioglu C : Ocular Behcet disease : current therapeutic approaches. Curr Opin Ophthalmol 2011 ; 22 : 508-516.
PubMed
2. Dunne JA,et al. : Double-blind clinical trial of topical steroids in anterior uveitis. Br J Ophthalmol 1979 ; 63 : 762-767.
PubMed
P.76 掲載の参考文献
1. Ohno S, et al. : Behcet's disease. In : Zierhut M, et al. (eds) : Intraocular Inflammation. Springer-Verlag Berlin Heidelberg, Heidelberg, 2016 : 785-795.
 
P.77 掲載の参考文献
1. Okada AA, et al. : Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol 2003 ; 87 : 968-971.
PubMed
1. Evereklioglu C : Ocular Behcet disease : current therapeutic approaches. Curr Opin Ophthalmol 2011 ; 22 : 508-516.
PubMed
2. Sen HN, et al. : Periocular corticosteroid injections in uveitis : effects and complications. Ophthalmology 2014 ; 121 : 2275-2286.
PubMed
3. Ohno S, et al. : Behcet's disease. In : Zierhut M, et al. (eds) : Intraocular Inflammation. Springer-Verlag Berlin Heidelberg, Heidelberg, 2016 ; 785-795.
 
4. Markomichelakis N, et al. : A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease : a comparative 4-week study. Rheumatology (Oxford) 2011 ; 50 : 593-597.
PubMed
P.78 掲載の参考文献
1. Matsumura N, et al. : Leucocyte movement and colchicine treatment in Behcet's disease. Lancet 1975 ; 2 : 813.
PubMed
1. Evereklioglu C : Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005 ; 50 : 297-350.
PubMed
2. 三村康男 : ベーチェット病の眼病変に対するコルヒチンの使用経験. 眼紀 1975 ; 26 : 902-908.
 
3. 松尾信彦, 他 : ベーチェット病のコルヒチン療法. 厚生省特定疾患ベーチェット病調査研究班 昭和51年度研究業績集 (班長 ; 清水保). 1977 : 147-151.
 
4. 水島裕, 他 : ベーチェット病のコルヒチン療法. リウマチ 1978 ; 18 : 112-115.
 
5. 熊代修 : 眼疾患に対するコルヒチン療法の研究. 眼紀 1984 ; 35 : 636-643.
 
6. 大野重昭, 他 : ベーチェット病眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
7. Levy-Clarke G, et al. : Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014 ; 121 : 785-796.
 
8. 蕪城俊克 : これからの非感染性ぶどう膜炎の治療戦略. あたらしい眼科 2017 ; 34 : 505-511.
Medical*Online
P.79 掲載の参考文献
1. 三村康男 : ベーチェット病の眼病変に対するコルヒチンの使用経験. 眼紀 1975 ; 26 : 902-908.
 
2. 斎藤一宇, 他 : Behcet病のコルヒチン療法の検討. 眼科 1977 ; 19 : 115-120.
 
3. 松尾信彦, 他 : ベーチェット病のコルヒチン療法. 厚生省特定疾患ベーチェット病調査研究班 昭和51年度研究業績集 (班長 ; 清水保). 1977 : 147-151.
 
4. Sarica K, et al. : Urological evaluation of Behcet patients and the effect of colchicine on fertility. Eur Urol 1995 ; 27 : 39-42.
PubMed
5. 柴田興一, 他 : サイクロスポリン使用中にミオパチーを呈したBehcet's病の一症例. 臨床神経学 1991 ; 31 : 847-852.
 
6. 高本光子, 他 : コルヒチンにより血清中CK上昇を認めたベーチェット病の6例. 臨眼 2005 ; 59 : 1691-1694.
 
P.80 掲載の参考文献
1. Masuda K, et al. : Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989 ; 1 : 1093-1096.
PubMed
1. 望月學, 他 : 非感染性ぶどう膜炎におけるネオーラルの安全使用マニュアル 2013年版. 5-26.
 
2. ネオーラル添付文書. 日本標準商品分類番号 873999. 2018年7月改訂 (第22版).
 
2. 小竹聡, 他 : ベーチェット病の眼症状に対する低用量シクロスポリン療法. 日眼会誌 1992 ; 96 : 1290-1294.
 
3. 大野重昭, 他 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
3. 大野重昭, 他 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
4. Yamada Y, et al. : Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010 ; 94 : 284-288.
PubMed
5. Fujino Y, et al. : Ciclosporin microemulsion preconcentrate treatment of patients with Behcet's disease. Jpn J Ophthalmol 1999 ; 43 : 318-326.
PubMed
P.81 掲載の参考文献
1. ネオーラル添付文書. 日本標準商品分類番号 873999. 2018年7月改訂 (第22版).
 
2. 大野重昭, 他 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
3. Kotter I, et al. : CNS involvement occurs more frequently in patients with Behcet's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases. Clin Rheumatol 2006 ; 25 : 482-486.
PubMed
4. Kotake S, et al. : Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999 ; 106 : 586-589.
PubMed
5. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
P.82 掲載の参考文献
1. ネオーラル添付文書. 日本標準商品分類番号 873999. 2018年7月改訂 (第22版).
 
1. 高本光子, 他 : コルヒチンにより血清中CK 上昇を認めたベーチェット病の6例. 臨眼 2005 ; 59 : 1691-1694.
 
2. 大野重昭, 他 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
2. ネオーラル添付文書. 日本標準商品分類番号 873999. 2018年7月改訂 (第22版).
 
3. 望月學, 他 : 非感染性ぶどう膜炎におけるネオーラルの安全使用マニュアル 2013年版. 5-26.
 
3. Ben-Chetrit E, et al. : Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 1994 ; 21 : 710-713.
PubMed
4. Nussenblatt RB, et al. : Cyclosporine : immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986 ; 31 : 159-169.
PubMed
4. コルヒチン添付文書. 日本標準商品分類番号 873941. 2016年9月改訂 (第12版)
 
P.83 掲載の参考文献
1. Hayasaka, S et al. : Visual prognosis in patients with Behcet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Ophthalmologica 1994 ; 208 : 210-213.
PubMed
2. 松浦岳司, 他 : 眼ベーチェット病治療におけるステロイド薬全身投与の再評価. 臨眼 1998 ; 52 : 670-674.
 
3. 藤野雄次郎, 他 : ぶどう膜炎治療の問題点-ベーチェット病. 眼科 1999 ; 41 : 1401-1408.
 
4. 川野庸一, 他 : ベーチェット病眼病変に対するステロイド薬長期間継続併用投与. 眼科 2000 ; 42 : 421-428.
 
5. 湯浅武之助, 他 : ベーチェット病の眼病変に対するステロイドの長期持続投与法. 厚生省特定疾患ベーチェット病調査研究班 平成6年度研究業績 (班長 ; 坂根剛). 1995 ; 165-167.
 
P.84 掲載の参考文献
1. Ohno S, et al. : Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-1368.
PubMed
1. Markomichelakis N, et al. : A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease : a comparative 4-week study. Rheumatology (Oxford) 2011 ; 50 : 593-597.
PubMed
2. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
2. Sfikakis PP, et al. : Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades?Behcet disease. Ann Intern Med 2004 ; 140 : 404-406.
PubMed
3. Tugal-Tutkun I, et al. : Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease : an open-label trial. Arthritis Rheum 2005 ; 52 : 2478-2484.
PubMed
4. Okada AA, et al. : Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012 ; 130 : 592-598.
PubMed
5. Takeuchi M, et al. : Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease : a multicenter study. Ophthalmology 2014 ; 121 : 1877-1884.
 
P.85 掲載の参考文献
1. Ohno S, et al. : Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-1368.
PubMed
2. Niccoli L, et al. : Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease : a 24-month follow-up study. Rheumatology (Oxford) 2007 ; 46 : 1161-1164.
PubMed
3. Al-Rayes H, et al. : Safety and efficacy of infliximab therapy in active behcet's uveitis : an open-label trial. Rheumatol Int 2008 ; 29 : 53-57.
PubMed
4. Vallet H, et al. : Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease : Multicenter study of 124 patients. J Autoimmun 2015 ; 62 : 67-74.
 
5. Takeuchi M, et al. : Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease : a multicenter study. Ophthalmology 2014 ; 121 : 1877-1884.
 
6. Fabiani C, et al. : Ten-Year Retention Rate of Infliximab in Patients with Behcet's Disease-Related Uveitis. Ocul Immunol Inflamm 2019 ; 27 : 34-39.
PubMed
P.86 掲載の参考文献
1. Kawaguchi T, et al. : Clinical course of patients with Behcet's uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol 2014 ; 58 : 75-80.
PubMed
1. Yamada Y, et al. : Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol 2011 ; 95 : 205-208.
PubMed
2. Takeuchi M, et al. : Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease : a multicenter study. Ophthalmology 2014 ; 121 : 1877-1884.
 
2. 申請資料概要 (レミケード点滴静注用100に関する資料. 2007年1月26日). http://www.pmda.go.jp/drugs/2007/P200700009/index.html (アクセス日 : 2019年8月22日)
 
3. Magro-Checa C, et al. : Life-threatening vasculo-Behcet following discontinuation of infliximab after three years of complete remission. Clin Exp Rheumatol 2013 ; 31 (Suppl 77) : 96-98.
 
P.87 掲載の参考文献
1. Sugita S, et al. : Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol 2011 ; 95 : 549-552.
PubMed
2. 大野重昭 : ベーチェット病における眼炎症発作とインフリキシマブトラフ値, サイトカイン血中濃度との相関および抗インフリキシマブ抗体と投与時反応の関連について. 厚生労働科学研究費補助金難治性疾患等克服研究事業 (難治性疾患克服研究事業) ベーチェット病に関する調査研究 平成25年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2013 : 51-55.
 
3. Pradeu T, et al. : The speed of change : towards a discontinuity theory of immunity? Nat Rev Immunol 2013 ; 13 : 764-769.
PubMed
4. Schaeverbeke T, et al. : Immunogenicity of biologic agents in rheumatoid arthritis patients : lessons for clinical practice. Rheumatology (Oxford) 2016 ; 55 : 210-220.
PubMed
P.88 掲載の参考文献
1. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
1. 後藤浩 : ベーチェット病に関する調査研究. 厚生労働科学研究費補助金難治性疾患等克服研究事業 (難治性疾患克服研究事業) ベーチェット病に関する調査研究 平成25年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2013 : 65-68.
 
2. Levy-Clarke G, et al. : Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014 ; 121 : 785-796.
 
2. Takeuchi M, et al. : Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behcet's disease. Ocul Immunol Inflamm 2012 ; 20 : 193-197.
PubMed
3. Tugal-Tutkun I, et al. : Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease : an open-label trial. Arthritis Rheum 2005 ; 52 : 2478-2484.
PubMed
3. 大野重昭, 他 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
4. Takeuchi M, et al. : Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 2005 ; 243 : 1147-1152.
PubMed
4. Capella MJ, et al. : Long-term efficacy and safety of infliximab in the treatment of Behcet's disease. Ocul Immunol Inflamm 2012 ; 20 : 198-202.
PubMed
5. Takeuchi M, et al. : Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease : a multicenter study. Ophthalmology 2014 ; 121 : 1877-1884.
 
6. Hinchey J, et al. : A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996 ; 334 : 494-500.
 
P.89 掲載の参考文献
1. Jaffe GJ, et al. : Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 2016 ; 375 : 932-943.
PubMed
2. Nguyen QD, et al. : Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II) : a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016 ; 388 : 1183-1192.
 
3. Interlandi E, et al. : Adalimumab for treatment of severe Behcet's uveitis : a retrospective long-term follow-up study. Clin Exp Rheumatol 2014 ; 32 (Suppl 84) : S58-62.
 
4. Fabiani C, et al. : Efficacy and safety of adalimumab in Behcet's disease-related uveitis : a multicenter retrospective observational study. Clin Rheumatol 2017 ; 36 : 183-189.
PubMed
P.90 掲載の参考文献
1. Bawazeer A, et al. : Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocular Immunol Inflamm 2010 ; 18 : 226-232.
PubMed
2. Interlandi E, et al. : Adalimumab for treatment of severe Behcet's uveitis : a retrospective long-term follow-up study. Clin Exp Rheumatol 2014 ; 32 (Suppl 84) : S58-62.
 
3. Calvo-Rio V, et al. : Anti-TNF-α therapy in patients with refractory uveitis due to Behcet's disease : a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 2014 ; 53 : 2223-2231.
 
4. Fabiani C, et al. : Efficacy and safety of adalimumab in Behcet's disease-related uveitis : a multicenter retrospective observational study. Clin Rheumatol 2017 ; 36 : 183-189.
PubMed
P.91 掲載の参考文献
1. Calvo-Rio V, et al. : Anti-TNF-α therapy in patients with refractory uveitis due to Behcet's disease : a 1-year follow-up study of 124 patients. Rheumatology 2014 ; 53 : 2223-2231.
 
P.92 掲載の参考文献
1. Levy-Clarke G, et al. : Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014 ; 121 : 785-796.
 
1. Martin-Varillas JL, et al. : Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behcet's Disease. Ophthalmology 2018 ; 125 : 1444-1451.
PubMed
2. 大野重昭, 他 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
2. Papp K, et al. : Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis : subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol 2013 ; 27 : 634-642.
PubMed
3. Tanaka Y, et al. : Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis : 1-year outcome of the HONOR study. Ann Rheum Dis 2015 ; 74 : 389-395.
PubMed
3. 蕪城俊克 : これからの非感染性ぶどう膜炎の治療戦略. あたらしい眼科 2017 ; 34 : 505-511.
Medical*Online
P.93 掲載の参考文献
1. Fabiani C, et al. : Efficacy and safety of adalimumab in Behcet's disease-related uveitis : a multicenter retrospective observational study. Clin Rheumatol 2017 ; 36 : 183-189.
PubMed
2. Calvo-Rio V, et al. : Anti-TNF-α therapy in patients with refractory uveitis due to Behcet's disease : a 1-year follow-up study of 124 patients. Rheumatology 2014 ; 53 : 2223-2231.
 
3. Koike T, et al. : Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of 7740 patients. Mod Rheumatol 2014 ; 24 : 390-398.
PubMed
4. Doran MF, et al. : Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002 ; 46 : 2294-2300.
PubMed
5. 厚生労働省 : 重篤副作用疾患別対応マニュアル (2006年11月21日).
 
6. Hinchey J, et al. : A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996 ; 334 : 494-500.
 
P.94 掲載の参考文献
1. 日本眼炎症学会TNF 阻害薬使用検討委員会 : 非感染性ぶどう膜炎に対するTNF阻害薬使用指針および安全対策マニュアル (2016年版). 日眼会誌 2017 : 121 : 34-41.
 
P.95 掲載の参考文献
1. Tabbara KF, et al. : Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol 2008 ; 146 : 845-850.
PubMed
2. Yamada Y, et al. : Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010 ; 94 : 284-288.
PubMed
3. 大野重昭, 他 : Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426.
 
P.96 掲載の参考文献
1. Okada AA, et al. : Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012 ; 130 : 592-598.
PubMed
1. Siddique SS, et al. : Glaucoma and uveitis. Surv Ophthalmol 2013 ; 58 : 1-10.
PubMed
2. Alfawaz A, et al. : Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease. Ann Saudi Med 2014 ; 34 : 328-333.
PubMed
2. 蕪城俊克, 他 : ぶどう膜炎による続発緑内障に対する外科療法. 眼科手術 2012 ; 25 : 211-216.
 
3. 陳進輝 : ぶどう膜炎続発緑内障に対する手術戦略. 眼科手術 2015 ; 28 : 518-524.
 
3. Sakai T, et al. : Intraocular surgery in patients receiving infliximab therapy for Behcet disease. Jpn J Ophthalmol 2010 ; 54 : 360-361.
PubMed
4. Ramdas WD, et al. : Efficacy of glaucoma drainage devices in uveitic glaucoma and a meta-analysis of the literature. Graefes Arch Clin Exp Ophthalmol 2019 ; 257 : 143-151.
 
4. Noda E, et al. : Cataract surgery under infliximab therapy in a patient with Behcet's disease. J Ocul Pharmacol Ther 2009 ; 25 : 467-470.
 
5. Mehta S, et al. : Outcomes of cataract surgery in patients with uveitis : a systematic review and meta-analysis. Am J Ophthalmol 2014 ; 158 : 676-692.
PubMed
5. Okada AA, et al. : Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012 ; 130 : 592-598.
PubMed
6. Takayama K, et al. : Short-term outcomes of coaxial microincision cataract surgery for uveitis-associated cataract without postoperative systemic steroid therapy. Ophthalmologica 2014 ; 231 : 111-116.
PubMed
7. 永本敏之 : ぶどう膜炎眼に対する白内障手術戦略. 眼科手術 2015 ; 28 : 512-517.
 
P.97 掲載の参考文献
1. Becker M, et al. : Vitrectomy in the treatment of uveitis. Am J Ophthalmol 2005 ; 140 : 1096-1105.
PubMed
1. 陳進輝 : ぶどう膜炎続発緑内障に対する手術戦略. 眼科手術 2015 ; 28 : 518-524
 
2. 外間英之, 他 : 内眼炎160眼の硝子体手術成績. 眼科手術 2004 ; 17 : 249-256.
 
3. 川野庸一, 他 : 硝子体手術を行ったベーチェット病症例の検討. 眼紀 2005 ; 56 : 797-800.
 
4. Dabour SA, et al. : Outcome of surgical management for rhegmatogenous retinal detachment in Behcet's disease. BMC Ophthalmol 2014 ; 14 : 61.
PubMed
5. Kerkhoff FT, et al. : Rhegmatogenous retinal detachment and uveitis. Ophthalmology 2003 ; 110 : 427-431.
PubMed
6. Sonoda KH, et al. : Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis : a case series study. Br J Ophthalmol 2003 ; 87 : 1010-1014.
PubMed
7. Okada AA, et al. : Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012 ; 130 : 592-598.
PubMed
P.98 掲載の参考文献
1. Giansanti F, et al. : Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol 2004 ; 14 : 445-448.
PubMed
P.99 掲載の参考文献
1. Hatemi G, et al. : EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-1662.
PubMed
2. Takeuchi A, et al. : Radiographic abnormalities in patients with Behcet's disease. Clin Exp Rheumatol 1984 ; 2 : 259-262.
PubMed
3. Frikha F, et al. : Destructive arthritis in Behcet's disease : a report of eight cases and literature review. Int J Rheum Dis 2009 ; 12 : 250-255.
PubMed
4. Yurdakul S, et al. : The arthritis of Behcet's disease : a prospective study. Ann Rheum Dis 1983 ; 42 : 505-515.
PubMed
5. Jeong H, et al. : Clinical courses and predictors of outcomes in patients with monoarthritis : a retrospective study of 171 cases. Int J Rheum Dis 2014 ; 17 : 502-510.
PubMed
6. Ceccarelli F, et al. : Knee joint synovitis in Behcet's disease : a sonographic study. Clin Exp Rheumatol 2007 ; 25 (Suppl 45) : S76-79.
 
7. Sugawara S, et al. : Hand and wrist arthritis of Behcet's disease : Imaging features. Acta Radiol 2010 ; 51 : 183-186.
PubMed
P.100 掲載の参考文献
1. Hatemi G, et al. : EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-1662.
PubMed
2. Ambrose NL, et al. : Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol 2013 ; 9 : 79-89.
PubMed
3. Yurdakul S, et al. : The arthritis of Behcet's disease : a prospective study. Ann Rheum Dis 1983 ; 42 : 505-515.
PubMed
4. Khan MA, et al. : A wider spectrum of spondyloarthropathies. Semin Arthritis Rheum 1990 ; 20 : 107-113.
 
5. Colina M, et al. : Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome : a single center study of a cohort of 71 subjects. Arthritis Rheum 2009 ; 61 : 813-821.
PubMed
6. Firestein GS, et al. : Mouth and genital ulcers with inflamed cartilage : MAGIC syndrome. Five patients with features of relapsing polychondritis and Behcet's disease. Am J Med 1985 ; 79 : 65-72.
PubMed
7. Ta keuchi A, et al. : Radiographic abnormalities in patients with Behcet's disease. Clin Exp Rheumatol 1984 ; 2 : 259-262.
 
P.101 掲載の参考文献
1. Simsek H, et al. : Treatment of Behcet disease with indomethacin. Int J Dermatol 1991 ; 30 : 54-57.
PubMed
1. Mat C, et al. : A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 2006 ; 45 : 348-352.
PubMed
2. Hatemi G, et al. : EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-1662.
PubMed
2. Hatemi G, et al. : EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-1662.
PubMed
3. Ambrose NL, et al. : Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol 2013 ; 9 : 79-89.
PubMed
P.102 掲載の参考文献
1. Yazici H, et al. : A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990 ; 322 : 281-285.
PubMed
1. Yurdakul S, et al. : A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-2692.
PubMed
2. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
2. Aktulga E, et al. : A double blind study of colchicine in Behcet's disease. Haematologica 1980 ; 65 : 399-402.
PubMed
3. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
3. Sfikakis PP, et al. : Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford) 2007 ; 46 : 736-741.
PubMed
4. 東野俊洋, 他 : 関節症状を有するベーチェット病患者の臨床特徴. 第63回日本リウマチ学会総会・学術集会プログラム・抄録集 2019. 2019 : 796.
 
P.103 掲載の参考文献
1. Sfikakis PP, et al. : Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford) 2007 ; 46 : 736-741.
PubMed
2. Atzeni F, et al. : Successful treatment of resistant Behcet's disease with etanercept. Clin Exp Rheumatol 2005 ; 23 : 729.
PubMed
3. Arida A, et al. : Anti-TNF agents for Behcet's disease : analysis of published data on 369 patients. Semin Arthritis Rheum 2011 ; 41 : 61-70.
PubMed
4. Iwata S, et al. : Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009 ; 48 : 1012-1013.
PubMed
5. Donghi D, et al. : Infliximab for the treatment of refractory Adamantiades-Behcet disease with articular, intestinal, cerebral and ocular involvement. Dermatology 2010 ; 220 : 282-286.
PubMed
6. Melikoglu M, et al. : Short-term trial of etanercept in Behcet's disease : a double blind, placebo controlled study. J Rheumatol 2005 ; 32 : 98-105.
PubMed
P.104 掲載の参考文献
1. International Study Group for Behcet's Disease : Criteria for diagnosis of Behcet's disease. Lancet ; 335 : 1078-1080.
 
2. Kirkali Z, et al. : Urological aspects of Behcet's disease. Br J Urol 1991 ; 67 : 638-639.
PubMed
3. Cho YH, et al. : Clinical features of patients with Behcet's disease and epididymitis. J Urol 2003 ; 170 : 1231-1233.
PubMed
4. Cetinel B, et al. : Urologic screening for men with Behcet's syndrome. Urology 1998 ; 52 : 863-865.
PubMed
5. Davatchi F, et al. : Adult Behcet's disease in Iran : analysis of 6075 patients. Int J Rheum Dis 2016 ; 19 : 95-103.
 
6. 黒澤美智子, 他 : ベーチェット病診療ガイドライン作成に向けて, 臨床調査個人票新規申請データで患者の実態を示す.厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) ベーチェット病に関する調査研究 平成27年度総括・分担研究報告書 (研究代表者 ; 水木信久). 2016 : 52-58.
 
7. Ideguchi H, et al. : Behcet disease : evolution of clinical manifestations. Medicine (Baltimore) 2011 ; 90 : 125-132.
PubMed
8. 中江公裕, 他 : ベーチェット病患者全国疫学調査成績 : 臨床疫学的成績とHLA-B51との関連. 厚生省特定疾患ベーチェット病調査研究班 平成4年度研究業績 (班長 ; 坂根剛). 1993 : 70-82.
 
P.105 掲載の参考文献
1. Kaklamani VG, et al. : Recurrent epididymo-orchitis in patients with Behcet's disease. J Urol 2000 ; 163 : 487-489.
PubMed
1. Trojian TH, et al. : Epididymitis and orchitis : an overview. Am Fam Physician 2009 ; 79 : 583-537.
PubMed
2. Sharquie KE, et al. : Epididymo-orchitis in Behcets disease. Br J Rheumatol 1987 ; 26 : 468-469.
PubMed
2. Kirkali Z, et al. : Urological aspects of Behcet's disease. Br J Urol 1991 ; 67 : 638-639.
PubMed
3. Pannek J, et al. : Orchitis due to vasculitis in autoimmune diseases. Scand J Rheumatol 1997 ; 26 : 151-154.
PubMed
3. Callejas-Rubio JL, et al. : Recurrent epididymo-orchitis secondary to Behcets disease. J Urol 1998 ; 160 : 496.
PubMed
4. Horii S, et al. : Case of Behcet's disease diagnosed by bilateral epididymitis. Hinyokika Kiyo 2014 ; 60 : 593-596.
PubMed
4. Silva CA, et al. : Diagnosis and classification of autoimmune orchitis. Autoimmun Rev 2014 ; 13 : 431-434.
PubMed
5. Ulukaradag E, et al. : Behcet's Disease Detecting by Attacks of Recurrent Epididymo-Orchitis : Case Reports. Urol J 2015 ; 12 : 2379-
PubMed
5. Kenneth T, et al. : Miscellaneous Manifestations of Behcet's Disease. In : Yazici Y, et al. (eds) : Behcet's Syndrome. Springer Science+Business Media, Berlin, 2010 : 189-204.
 
6. 黒沢美智子, 他 : 臨床調査個人票を用いたベーチェット病の予後の研究方法 新規受給者の1年後, 5年後の予後と1年後の予後に関連する要因. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23～25年度総合研究報告書 (研究代表者 ; 石ヶ坪良明). 2014 : 93-98.
 
P.106 掲載の参考文献
1. Cho YH, et al. : Clinical features of patients with Behcet's disease and epididymitis. J Urol 2003 ; 170 : 1231-1233.
PubMed
2. Kaklamani VG, et al. : Recurrent epididymo-orchitis in patients with Behcet's disease. J Urol 2000 ; 163 : 487-489.
PubMed
3. Pannek J, et al. : Orchitis due to vasculitis in autoimmune diseases. Scand J Rheumatol 1997 ; 26 : 151-154.
PubMed
4. Callejas-Rubio JL, et al. : Recurrent epididymo-orchitis secondary to Behcets disease. J Urol 1998 ; 160 : 496.
PubMed
5. 黒沢美智子, 他 : ベーチェット病診療ガイドライン作成に向けて, 臨床調査個人票新規申請データで患者の実態を示す. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) ベーチェット病に関する調査研究 平成27年度総括・分担研究報告書 (研究代表者 ; 水木信久). 2016 : 52-58.
 
6. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
P.107 掲載の参考文献
1. 岡崎和一, 他 : 腸管ベーチェット病の診断コンセンサス. INTESTINE 2014 ; 18 : 549-554.
 
2. 井上詠, 他 : 腸管ベーチェット病・単純性潰瘍. 山本博徳, 他 (編) : Visual 小腸疾患診療マニュアル. Medical View, 2011 : 112-121.
 
3. Hisamatsu T, et al. : Diagnosis and management of intestinal Behcet's disease. Clin J Gastroenterol 2014 ; 7 : 205-212.
PubMed
4. 厚生労働科学研究費補助金難治性疾患克服事業 原因不明小腸潰瘍症の実態把握, 疾患概念, 疫学, 治療体系の確立に関する研究 平成23年度研究報告書 (研究代表者 ; 日比紀文). 2012.
 
5. 黒澤美智子 : 日本におけるベーチェット病の臨床疫学像. リウマチ科 2015 ; 53 : 537-542.
 
6. Ideguchi H, et. al. : Gastrointestinal manifestations of Behcet's disease in Japan : a study of 43 patients. Rheumatol Int 2014 ; 34 : 851-856.
 
P.108 掲載の参考文献
1. Jung YS, et al. : Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
2. Maldini C, et al. : Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics : systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 2012 ; 51 : 887-900.
 
3. Tada Y, et al. : The association of Behcet's disease with myelodysplastic syndrome in Japan : a review of the literature. Clin Exp Rheumatol 2006 ; 24 (Suppl 42) : S115-119.
 
4. Kawabata H, et al. : Myelodysplastic syndrome complicated with inflammatory intestinal ulcers : significance of trisomy 8. Intern Med 2006 ; 45 : 1309-1314.
PubMed
P.109 掲載の参考文献
1. 日本ベーチェット病学会 : ベーチェット病の診断基準 (2016年小改訂). 2016. http://www-user.yokohama-cu.ac.jp/~jbehcet/jigyou/shindan.html (アクセス日 : 2019年10月23日)
 
2. Zou J, et al. : Endoscopic findings of gastrointestinal involvement in Chinese patients with Behcet's disease. World J Gastroenterol 2014 ; 20 : 17171-17178.
PubMed
3. Koklu S, et al. : Ileocolonic involvement in Behcet's disease : endoscopic and histological evaluation. Digestion 2010 ; 81 : 214-217.
PubMed
4. Yi SW, et al. : The prevalence and clinical characteristics of esophageal involvement in patients with Behcet's disease : a single center experience in Korea. J Korean Med Sci 2009 ; 24 : 52-56.
 
5. Lee CR, et al. : Colonoscopic findings in intestinal Behcet's disease. Inflamm Bowel Dis 2001 ; 7 : 243-249.
PubMed
6. Kim JS, et al. : Prediction of the clinical course of Behcet's colitis according to macroscopic classification by colonoscopy. Endoscopy 2000 ; 32 : 635-640.
PubMed
7. Lee SK, et al. : Differential diagnosis of intestinal Behcet's disease and Crohn's disease by colonoscopic findings. Endoscopy 2009 ; 41 : 9-16.
PubMed
8. Chae EJ, et al. : Radiologic and clinical findings of Behcet disease : comprehensive review of multisystemic involvement. Radiographics 2008 ; 28 : e31.
PubMed
9. Cheon JH, et al. : Development and validation of novel diagnostic criteria for intestinal Behcet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009 ; 104 : 2492-2499.
PubMed
10. 渡辺英伸, 他 : 回盲弁近傍の単純性潰瘍の病理. 胃と腸 1979 ; 14 : 749-767.
 
11. Matsukawa M, et al. : Endoscopic therapy with absolute ethanol for postoperative recurrent ulcers in intestinal Behcet's disease, and simple ulcers. J Gastroenterol 2001 ; 36 : 255-258.
PubMed
P.110 掲載の参考文献
1. Park MJ, et al. : Computed tomography enterography for evaluation of inflammatory bowel disease. Clin Endosc 2013 ; 46 : 327-366.
PubMed
1. 黒丸五郎 : 腸の局処病変観察について. 腸結核症の病理 結核新書 12. 医学書院, 1952 : 28.
 
2. Jung YS, et al. : Radiation exposure from abdominal imaging studies in patients with intestinal Behcet disease. Gut Liver 2014 ; 8 : 380-387.
PubMed
2. 武藤徹一郎, 他 : いわゆる "simple ulcer" とは. 胃と腸 1979 ; 14 : 739-748.
 
3. 渡辺英伸, 他 : 回盲弁近傍の単純性潰瘍の病理. 胃と腸 1979 ; 14 : 749-767.
 
4. 日本ベーチェット病学会 : ベーチェット病の診断基準 (2016年小改訂). 2016. http://www-user.yokohama-cu.ac.jp/~jbehcet/jigyou/shindan.html (アクセス日 : 2019年10月23日)
 
5. 岡部治弥, 他 : 仮称 "非特異性多発性小腸潰瘍症". 胃と腸 1968 ; 3 : 1539-1549.
 
6. Umeno J, et al. : A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter. PLoS Genet 2015 ; 11 : e1005581.
PubMed
P.111 掲載の参考文献
1. 渡辺英伸, 他 : 回盲弁近傍の単純性潰瘍の病理. 胃と腸 1979 ; 14 : 749-767.
 
2. 岩下明徳, 他 : 小腸の潰瘍性病変の病理. 外科 1985 ; 47 : 1025-1033.
 
3. 太田敦子, 他 : 腸管ベーチェット病と単純性潰瘍 : 病理像. INTESTINE 2014 ; 18 : 555-559.
 
4. Hayasaki N, et al. : Neutrophilic phlebitis is characteristic of intestinal Behcet's disease and simple ulcer syndrome. Histopathology 2004 ; 45 : 377-383.
PubMed
5. Imamura Y, et al. : Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol 2005 ; 139 : 371-378.
PubMed
6. 久松理一 : 腸管ベーチェット病診療コンセンサス・ステートメント改訂案 (2013年度版)
 
P.112 掲載の参考文献
1. 久松理一 : 腸管ベーチェット病診療コンセンサス・ステートメント改訂案 (2013年度版).
 
1. Jung YS, et al. : Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013 ; 58 : 496-503.
PubMed
2. Jung YS, et al. : Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease. Inflamm Bowel Dis 2012 ; 18 : 1064-1071.
PubMed
2. Cheon JH, et al. : Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 605-613.
PubMed
3. Lee HJ, et al. : Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol 2012 ; 18 : 5771-5778.
PubMed
3. Jung YS, et al. : Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
4. Skef W, et al. : Gastrointestinal Behcet's disease : a review. World J Gastroenterol 2015 ; 21 : 3801-3812.
PubMed
4. Naganuma M, et al. : Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet's disease. Am J Gastroenterol 2000 ; 95 : 2848-2851.
PubMed
5. Kimura Y, et al. : Characteristics of patients withintestinal Behcet's disease requiring treatment with immunosuppressants or anti-TNFα antibody. Mod Rheumatol 2016 ; 26 : 132-137.
 
6. Kasahara Y, et al. : Intestinal involvement in Behcet's disease : review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 1981 ; 24 : 103-106.
PubMed
7. Iida M, et al. : Postoperative recurrence in patients with intestinal Behcet's disease. Dis Colon Rectum 1994 ; 37 : 16-21.
PubMed
8. Baek SJ, et al. : Surgical Ttreatment and Outcomes in Patients With Intestinal Behcet Disease : Long-term Experience of a Single Large-Volume Center. Dis Colon Rectum 2015 ; 58 : 575-581.
 
9. Jung YS, et al. : Prognostic factors and long term clinical outcome for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 1594-1602.
PubMed
P.113 掲載の参考文献
1. Skef W, et al. : Gastrointestinal Behcet's disease : a review. World J Gastroenterol 2015 ; 21 : 3801-3812.
PubMed
1. Jung YS, et al. : Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 1594-1602.
PubMed
2. Tanida S, et al. : Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015 ; 13 : 940-948.
PubMed
2. Cheon JH, et al. : Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 605-613.
PubMed
3. Jung YS, et al. : Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 2130-2137.
PubMed
3. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
4. Ma D, et al. : Etanercept in the treatment of intestinal Behcet's disease. Cell Biochem Biophys 2014 ; 69 : 735-739.
PubMed
5. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
 
P.114 掲載の参考文献
1. Choi IJ, et al. : Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum 2000 ; 43 : 692-700.
PubMed
2. Jung YS, et al. : Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 1594-1602.
PubMed
3. Cheon JH, et al. : An update on the diagnosis, treatment, and prognosis of intestinal Behcet's disease. Curr Opin Rheumatol 2015 ; 27 : 24-31.
PubMed
4. Lee HJ, et al. : Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol 2012 ; 18 : 5771-5778.
PubMed
5. Yim SM, et al. : Mucosal healing predicts the long-term prognosis of intestinal Behcet's disease. Dig Dis Sci 2014 ; 59 : 2529-2935.
 
6. Maruyama Y, et al. : A case of intestinal Behcet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med 2012 ; 51 : 2125-2129.
PubMed
7. Naganuma M, et al. : Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008 ; 14 : 1259-1264.
PubMed
8. Tanida S, et al. : Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015 ; 13 : 940-948.
PubMed
9. Iwata S, et al. : Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011 ; 21 : 184-191.
 
P.115 掲載の参考文献
1. Jung YS, et al. : Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
2. Ikezawa K, et al. : A case of Behcet's syndrome with esophageal involvement treated with salicylazosulfapyridine and prednisolone. Endoscopy 1998 ; 30 : S52-53.
PubMed
3. Park JJ, et al. : Long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behget's disease. Gastroenterology 2010 ; 138 : S698-S699.
 
4. Toda K, et al. : Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behcet's disease. J Gastroenterol 2002 ; 37 : 844-848.
PubMed
5. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
6. Naganuma M, et al. : Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008 ; 14 : 1259-1264.
PubMed
7. Kinoshita H, et al. : Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication. Intern Med 2013 ; 52 : 1855-1862.
PubMed
8. Lee JH, et al. : Efficacy of infliximab in intestinal Behcet's disease : a Korean multicenter retrospective study. Inflamm Bowel Dis 2013 ; 19 : 1833-1838.
 
9. Tanida S, et al. : Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015 ; 13 : 940-948.
PubMed
10. 小林清典, 他 : 腸型ベーチェット病に対する栄養療法の臨床的研究. 日本大腸肛門病学会誌 1989 : 42 ; 1265-1271.
 
11. Matsumura K, et al. : Efficacy of oral tacrolimus on intestinal Behcet's disease. Inflamm Bowel Dis 2010 ; 16 : 188-189.
PubMed
P.116 掲載の参考文献
1. Jung YS, et al. : Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
2. Park MS et al. : Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Dig Dis Sci 2015 ; 60 : 195-204.
PubMed
3. Jung YS, et al. : Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis 2012 ; 18 : 750-757.
PubMed
4. Iwata S, et al. : Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behc et's disease. Mod Rheumatol 2011 ; 21 : 184-191.
 
5. 小林清典, 他 : 腸型ベーチェット病に対する栄養療法の臨床的研究. 日本大腸肛門病学会誌 1989 : 42 ; 1265-1271.
 
6. Naganuma M, et al. : Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008 ; 14 : 1259-1264.
PubMed
7. Lee JH, et al. : Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007 ; 22 : 24-27.
PubMed
8. Tanida S, et al. : Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015 ; 13 : 940-948.
PubMed
9. Ariyachaipanich A, et al. : Intestinal Behcet's disease : maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009 ; 15 : 1769-1771.
PubMed
P.117 掲載の参考文献
1. Cheon JH, et al. : An update on the diagnosis, treatment, and prognosis of intestinal Behcet's disease. Curr Opin Rheumatol 2015 ; 27 : 24-31.
PubMed
1. Jung YS, et al. : Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
2. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
 
2. Skef W, et al. : Gastrointestinal Behcet's disease : a review. World J Gastroenterol 2015 ; 21 : 3801-3812.
PubMed
3. Hisamatsu T, et al. : Diagnosis and management of intestinal Behcet's disease. Clin J Gastroenterol 2014 ; 7 : 205-212.
PubMed
4. Sakane T, et al. : Behcet's disease. N Engl J Med 1999 ; 341 : 1284-1291.
PubMed
5. Kobayashi K, et al. : Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol 2007 ; 42 : 737-745.
PubMed
6. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
 
7. Grigg EL, et al. : Mimicry and deception in inflammatory bowel disease and intestinal behcet disease. Gastroenterol Hepatol (NY) 2012 ; 8 : 103-112.
 
8. Saleh Z, et al. : Update on the therapy of Behcet disease. Ther Adv Chronic Dis 2014 ; 5 : 112-134.
PubMed
9. Park JJ, et al. : Long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behget's disease. Gastroenterology 2010 ; 138 : S698-S699.
 
P.118 掲載の参考文献
1. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
 
2. Jung YS, et al. : Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis 2012 ; 18 : 750-757.
PubMed
3. Park MS, et al. : Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Dig Dis Sci 2015 ; 60 : 195-204.
PubMed
4. Choi IJ, et al. : Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum 2000 ; 43 : 692-700.
PubMed
5. Lee HW, et al. : Postoperative Effects of Thiopurines in Patients with Intestinal Behcet's Disease. Dig Dis Sci 2015 ; 60 : 3721-3727.
PubMed
6. Iwata S, et al. : Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011 ; 21 : 184-191.
 
P.119 掲載の参考文献
1. Yang SK, et al. : A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014 ; 46 : 1017-1020.
PubMed
2. Kakuta Y, et al. : NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J 2016 ; 16 : 280-285.
PubMed
3. Asada A, et al. : NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J Gastroenterol 2016 ; 51 : 22-29.
PubMed
4. Kakuta Y, et al. : NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol 2018 ; 53 : 1065-1078.
PubMed
5. Wilson A, et al. : HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2018 ; 47 : 615-620.
 
P.120 掲載の参考文献
1. 小林清典, 他 : 腸型ベーチェット病に対する栄養療法の臨床的研究. 日本大腸肛門病学会誌 1989 ; 42 : 1265-1271.
 
2. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
 
P.121 掲載の参考文献
1. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFa monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
PubMed
1. Tanida S, et al. : Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015 ; 13 : 940-948.
PubMed
2. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
2. Samama MM, et al. : Quantification of risk factors for venous thromboembolism : a preliminary study for the development of a risk assessment tool. Haematologica 2003 ; 88 : 1410-1121.
PubMed
3. Vallet H, et al. : Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease : Multicenter study of 124 patients. J Autoimmun 2015 ; 62 : 67-74.
 
4. Kinoshita H, et al. : Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication. Intern Med 2013 ; 52 : 1855-1862.
PubMed
P.122 掲載の参考文献
1. Matsumura K, et al. : Efficacy of oral tacrolimus on intestinal Behcet's disease. Inflamm Bowel Dis 2010 ; 16 : 188-189.
PubMed
1. Naganuma M, et al. : Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet's disease. Am J Gastroenterol 2000 ; 95 : 2848-2851.
PubMed
2. Baek SJ, et al. : Surgical Treatment and Outcomes in Patients With Intestinal Behcet Disease : Long-term Experience of a Single Large-Volume Center. Dis Colon Rectum 2015 ; 58 : 575-581.
PubMed
3. 馬場正三 : 腸型Behcet病の臨床. 胃と腸 1979 ; 14 : 885-892.
 
4. Iida M, et al. : Postoperative recurrence in patients with intestinal Behcet's disease. Dis Colon Rectum 1994 ; 37 : 16-21.
PubMed
5. Kasahara Y, et al. : Intestinal involvement of Behcet's disease : Review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 1981 ; 24 : 103-106.
PubMed
P.123 掲載の参考文献
1. Naganuma M, et al. : Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet's disease. Am J Gastroenterol 2000 ; 95 : 2848-2851.
PubMed
2. Iida M, et al. : Postoperative recurrence in patients with intestinal Behcet's disease. Dis Colon Rectum 1994 ; 37 : 16-21.
PubMed
3. Baek SJ, et al. : Surgical Treatment and Outcomes in Patients With Intestinal Behcet Disease : Long-term Experience of a Single Large-Volume Center. Dis Colon Rectum 2015 ; 58 : 575-581.
PubMed
4. Jung YS, et al. : Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm 123
 
5. Kasahara Y, et al. : Intestinal involvement of Behcet's disease : Review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 1981 ; 24 : 103-106.
PubMed
6. Choi IJ, et al. : Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum 2000 ; 43 : 692-700.
PubMed
7. Hur H, et al. : Patterns of recurrence and prognosis in patients with intestinal Behcet's disease who underwent a bowel resection. J Korean Soc Coloproctol 2008 ; 24 : 166-174.
 
8. 馬場正三 : 腸型Behcet病の臨床. 胃と腸 1979 ; 14 : 885-892.
 
P.124 掲載の参考文献
1. Hisamatsu T, et al. : The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFa monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-162.
PubMed
2. Baek SJ, et al. : Surgical Treatment and Outcomes in Patients With Intestinal Behcet Disease : Long-term Experience of a Single Large-Volume Center. Dis Colon Rectum 2015 ; 58 : 575-581.
PubMed
3. Jung YS, et al. : Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 1594-1602.
PubMed
4. Jung YS, et al. : Long-term clinical outcomes of Crohn's disease and intestinal Behcet's disease. Inflamm Bowel Dis 2013 ; 19 : 99-105.
 
5. Lee HW, et al. : Postoperative Effects of Thiopurines in Patients with Intestinal Behcet's Disease. Dig Dis Sci 2015 ; 60 : 3721-3727.
PubMed
P.125 掲載の参考文献
1. Fujikawa S, et al. : Behcet disease in children : a nationwide retrospective survey in Japan. Acta Pediatr Jpn 1997 ; 39 : 285-289.
 
2. Nishiyama M, et al. : A study of comparison between the nationwide epidemiological survey in 1991 and previous surveys on behcet's disease in Japan. Environ Health Prev Med 1999 ; 4 : 130-134.
PubMed
3. Tabata M, et al. : Intestinal Behcet's disease : a case report and review of Japanese reports in children. J Pediatr Gastroenterol Nutr 1999 ; 29 : 447-481.
 
4. Krause I, et al. : Childhood Behcet's disease : clinical features and comparison with adult-onset disease. Rheumtology (Oxford) 1999 ; 38 : 457-462.
 
5. Kone-Paut I, et al. : Consensus classification criteria for paediatric Behcet's disease from a prospective observational cohort : PEDBD. Ann Rheum Dis 2016 ; 75 : 958-964.
PubMed
6. Kone-Paut I : Behcet's disease in children, an overview. Pediatr Rheumatol Online J 2016 ; 14 : 10.
PubMed
7. Iwama I, et al. : Anti-tumor necrosis factor monoclonal antibody therapy for intestinal Behcet disease in an adolescent. J Pediatr Gastroenterol Nutr 2011 ; 53 : 686-688.
 
8. Yasui K, et al. : Thalidomide for treatment of intestinal involvement of juvenile-onset Behcet disease. Inflamm Bowel Dis 2008 ; 14 : 396-400.
PubMed
9. 山澤弘州, 他 : ステロイド療法中に大量下血をきたした腸管ベーチェットの1男児例. 臨床小児医学 2000 ; 48 : 61-64.
 
P.126 掲載の参考文献
1. Esatoglu SN, et al. : A reappraisal of the association between Behcet's disease, myelodysplastic syndrome and the presence of the trisomy 8 : a systematic literature review. Clin Exp Rheumatol 2015 ; 33 (Suppl 94) : S145-151.
 
2. Ahn JK, et al. : Behcet's disease associated with bone marrow failure in Korean patients : clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford) 2008 ; 47 : 1228-1230.
PubMed
3. Riccardi VM : Trisomy 8 : an international study of 70 patients. Birth Defects Orig Artic Ser 1977 ; 13 : 171-184.
 
4. Tada Y, et al. : The association of Behcet's disease with myelodysplastic syndrome in Japan : a review of the literature. Clin Exp Rheumatol 2006 ; 24 (Suppl 42) : S115-119.
 
5. Kawabata H, et al. : Myelodysplastic syndrome complicated with inflammatory intestinal ulcers : significance of trisomy 8. Intern Med 2006 ; 45 : 1309-1314.
PubMed
6. Soysal T, et al. : Bone marrow transplantation for Behcet's disease : a case report and systematic review of the literature. Rheumatology (Oxford) 2014 ; 53 : 1136-1141.
PubMed
7. Kimura M, et al. : Usefulness of Adalimumab for Treating a Case of Intestinal Behcet's Disease With Trisomy 8 Myelodysplastic Syndrome. Intest Res 2015 ; 13 : 166-169.
PubMed
8. Tanaka H, et al. : Successful treatment by azacitidine therapy of intestinal Behcet's disease associated with myelodysplastic syndrome. Int J Hematol 2013 ; 97 : 520-524.
PubMed
P.127 掲載の参考文献
1. Ames PR, et al. : Thrombosis in Behcet's disease : a retrospective survey from a single UK centre. Rheumatology (Oxford) 2001 ; 40 : 652-655.
PubMed
2. 石ヶ坪良明, 他 : 血管ベーチェット病の臨床像 : ベーチェット病研究班内調査-全国疫学調査と自験例との比較. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2012 : 76-82.
 
3. Takeno M, et al. : Vascular involvement of Behcet's disease. In : Ishigatsubo Y (eds) : Behcet's Disease. Springer Japan, 2015 : 79-100.
 
4. Desbois AC, et al. : Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012 ; 64 : 2753-2760.
PubMed
5. Wu X, et al. : Behcet's disease complicated with thrombosis : a report of 93 Chinese cases. Medicine (Baltimore) 2014 ; 93 : e263.
PubMed
6. Seyahi E, et al. : Pulmonary artery involvement and associated lung disease in Behcet disease : a series of 47 patients. Medicine (Baltimore) 2012 ; 91 : 35-48.
PubMed
P.128 掲載の参考文献
1. 石ヶ坪良明, 他 : 血管ベーチェット病の臨床像 : ベーチェット病研究班内調査-全国疫学調査と自験例との比較. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2012 : 76-82.
 
1. 石ヶ坪良明, 他 : 血管ベーチェット病の臨床像 : ベーチェット病研究班内調査-全国疫学調査と自験例との比較. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2012 : 76-82.
 
2. Seyahi E, et al. : Pulmonary artery involvement and associated lung disease in Behcet disease : a series of 47 patients. Medicine (Baltimore) 2012 ; 91 : 35-48.
PubMed
2. Saadoun D, et al. : Long-term outcome of arterial lesions in Behcet disease : a series of 101 patients. Medicine (Baltimore) 2012 ; 91 : 18-24.
PubMed
3. Tuzun H, et al. : Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. J Vasc Surg 2012 ; 55 : 157-163.
PubMed
3. Celik S, et al. : Pulmonary artery aneurysms in Behcet's syndrome : a review of the literature with emphasis on geographical differences. Clin Exp Rheumatol 2015 ; 33 (Suppl 94) : S54-59.
 
4. Wu X, et al. : Behcet's disease complicated with thrombosis : a report of 93 Chinese cases. Medicine (Baltimore) 2014 ; 93 : e263.
PubMed
4. Soussan M, et al. : Management of large-vessel vasculitis with FDG-PET : a systematic literature review and meta-analysis. Medicine (Baltimore) 2015 ; 94 : e622.
PubMed
5. Reus M, et al. : Treatment of a radial artery pseudoaneurysm with ultrasound-guided percutaneous thrombin injection in a patient with Behcet's syndrome. J Clin Ultrasound 2003 ; 31 : 440-444.
 
5. Bilgin G, et al. : Systemic and pulmonary screening of patients with Behcet's disease during periodic follow-up. Respir Med 2013 ; 107 : 466-471.
PubMed
P.129 掲載の参考文献
1. Jeong DS, et al. : Long-term experience of surgical treatment for aortic regurgitation attributable to Behcet's disease. Ann Thorac Surg 2009 ; 87 : 1775-1782.
PubMed
2. Ma WG, et al. : Aortic regurgitation caused by Behcet's disease : surgical experience during an 11-year period. J Card Surg 2012 ; 27 : 39-44.
PubMed
3. Mogulkoc N, et al. : Intracardiac thrombus in Behcet's disease : a systematic review. Chest 2000 ; 118 : 479-487.
PubMed
4. Gullu IH, et al. : Silent myocardial ischemia in Behcet's disease. J Rheumatol 1996 ; 23 : 323-327.
PubMed
5. Reus M, et al. : Treatment of a radial artery pseudoaneurysm with ultrasound-guided percutaneous thrombin injection in a patient with Behcet's syndrome. J Clin Ultrasound 2003 ; 31 : 440-444.
 
6. Geri G, et al. : Spectrum of cardiac lesions in Behcet disease : a series of 52 patients and review of the literature. Medicine (Baltimore) 2012 ; 91 : 25-34.
PubMed
P.130 掲載の参考文献
1. 石ヶ坪良明, 他 : 血管ベーチェット病の臨床像 : ベーチェット病研究班内調査-全国疫学調査と自験例との比較. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2012 : 76-82.
 
2. Takeno M, et al. : Vascular Involvement of Behcet's disease. In : Ishigatsubo Y (eds) : Behcet's Disease. Springer Japan, 2015 : 79-100.
 
3. Ideguchi H, et al. : Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 2011 ; 29 (Suppl 67) : S47-53.
 
4. Tascilar K, et al. : Vascular involvement in Behcet's syndrome : a retrospective analysis of associations and the time course. Rheumatology (Oxford) 2014 ; 53 : 2018-2022.
PubMed
5. 日本循環器学会, 他 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018 : 68-77.
 
6. 太田覚史, 他 : 静脈血栓塞栓症の発症機序とリスク因子. EBNursing 2007 ; 7 : 278-282.
Medical*Online
7. La Regina M, et al. : Behcet's Disease as a Model of Venous Thrombosis. Open Cardiovasc Med J 2010 ; 23 : 71-77.
 
P.131 掲載の参考文献
1. Ideguchi H, et al. : Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 2011 ; 29 (Suppl 67) : S47-53.
 
2. Terao C, et al. : Takayasu Arteritis and Ulcerative Colitis : High Rate of Co-Occurrence and Genetic Overlap. Arthritis Rheumatol 2015 ; 67 : 2226-2232.
PubMed
P.132 掲載の参考文献
1. Seyahi E, et al. : Pulmonary artery involvement and associated lung disease in Behcet disease : a series of 47 patients. Medicine (Baltimore) 2012 ; 91 : 35-48.
PubMed
1. Bodur H, et al. : Quality of life and life satisfaction in patients with Behcet's disease : relationship with disease activity. Clin Rheumatol 2006 ; 25 : 329-333.
PubMed
2. Khalid U, et al. : Hughes-Stovin syndrome. Orphanet J Rare Dis 2011 ; 6 : 15.
PubMed
3. Loeys BL, et al. : Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006 ; 355 : 788-798.
PubMed
P.133 掲載の参考文献
1. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
1. 石ヶ坪良明, 他 : 血管ベーチェット病の臨床像 : ベーチェット病研究班内調査-全国疫学調査と自験例との比較. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23年度総括・分担研究報告書 (研究代表者 ; 石ヶ坪良明). 2012 : 76-82.
 
2. Alibaz-Oner F, et al. : Behcet disease with vascular involvement : effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore) 2015 ; 94 : e494.
PubMed
2. Mehta P, et al. : Thrombosis and Behcet's syndrome in non-endemic regions. Rheumatology (Oxford) 2010 ; 49 : 2003-2004.
PubMed
3. Desbois AC, et al. : Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012 ; 64 : 2753-2760.
PubMed
3. Ahn JK, et al. : Treatment of venous thrombosis associated with Behcet's disease : immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008 ; 27 : 201-205.
PubMed
4. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
4. Seyahi E, et al. : An outcome survey of 43 patients with Budd-Chiari syndrome due to Behcet's syndrome followed up at a single, dedicated center. Semin Arthritis Rheum 2015 ; 44 : 602-609.
 
5. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
5. 日本循環器学会, 他 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2009 : 68-77.
 
6. Boban A, et al. : Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behcet Disease with Rivaroxaban. Case Rep Hematol 2016 ; 2016 : 2164329.
PubMed
7. Mismetti P, et al. : Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism A Randomized Clinical Trial. JAMA 2015 ; 313 : 1627-1635.
PubMed
P.134 掲載の参考文献
1. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
2. Saadoun, D. et al. : Long-term outcome of arterial lesions in Behcet disease : a series of 101 patients. Medicine (Baltimore) 2012 ; 91 : 18-24.
PubMed
3. Tuzun H, et al. : Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. J Vasc Surg 2012 ; 55 : 157-163.
PubMed
4. Liu Q, et al. : Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Behcet disease. Surgery 2016 ; 159 : 1422-1429.
PubMed
5. 日本高血圧学会 : 臓器障害を合併する高血圧. 高血圧治療ガイドライン. 2014 : 58-74.
 
P.135 掲載の参考文献
1. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
1. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
2. Hamuryudan V, et al. : Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004 ; 117 : 867-870.
PubMed
2. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
3. Hamuryudan V, et al. : Pulmonary arterial aneurysms in Behcet's syndrome : a report of 24 cases. Br J Rheumatol 1994 ; 33 : 48-51.
PubMed
3. Seyahi E, et al. : Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome. Rheumatology (Oxford) 2007 ; 46 : 1213-1214.
PubMed
4. Seyahi E, et al. : Pulmonary artery involvement and associated lung disease in Behcet disease : a series of 47 patients. Medicine (Baltimore) 2012 ; 91 : 35-48.
PubMed
4. Adler S, et al. : Behcet's disease : successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res (Hoboken) 2012 ; 64 : 607-611.
PubMed
5. Chan E, et al. : Pulmonary artery aneurysms in Behcet's disease treated with anti-TNFα : A case series and review of the literature. Autoimmun Rev 2016 ; 15 : 375-358.
 
5. Hamuryudan V, et al. : Pulmonary artery involvement in Behcet's syndrome : Effects of anti-Tnf treatment. Semin Arthritis Rheum 2015 ; 45 : 369-736.
PubMed
6. Voiriot G, et al. : Transcatheter embolotherapy of pulmonary artery aneurysms as emergency treatment of hemoptysis in Behcet patients : experience of a referral center and a review of the literature. Intern Emerg Med 2018 ; 13 : 491-500.
 
6. Hamuryudan V, et al. : Pulmonary artery involvement in Behcet's syndrome : Effects of anti-Tnf treatment. Semin Arthritis Rheum 2015 ; 45 : 369-373.
PubMed
7. Emmi G, et al. : Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behcet's Syndrome : A Retrospective Study of Seventy Patients With Vascular Involvement. Arthritis Rheumatol 2018 ; 70 : 1500-1507.
PubMed
8. Magro-Checa C, et al. : Life-threatening vasculo-Behcet following discontinuation of infliximab after three years of complete remission. Clin Exp Rheumatol 2013 ; 31 (Suppl 77) : 96-98.
 
9. Nakamura A, et al. : Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behcet Disease. Case Rep Rheumatol 2016 ; 2016 : 1467583.
 
P.137 掲載の参考文献
1. 日本循環器学会 : 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版). 2012.
 
2. 日本循環器学会 : 大動脈瘤・大動脈解離診断ガイドライン (2011年改訂版). 2011.
 
3. Okada K, et al. : Surgical management of Behcet's aortitis : a report of eight patients. Ann Thorac Surg 1997 ; 64 : 116-119.
PubMed
4. Ando M, et al. : Surgical treatment of Behcet's disease involving aortic regurgitation. Ann Thorac Surg 1999 ; 68 : 2136-2140.
PubMed
5. Jeong DS, et al. : Long-term experience of surgical treatment for aortic regurgitation attributable to Behcet's disease. Ann Thorac Surg 2009 ; 87 : 1775-1782.
PubMed
6. Ma WG, et al. : Aortic regurgitation caused by Behcet's disease : surgical experience during an 11-year period. J Card Surg 2012 ; 27 : 39-44.
PubMed
7. Erentug V, et al. : Valvular surgery in Behcet's disease. J Card Surg 2006 ; 21 : 289-291.
PubMed
8. Azuma T, et al. : Aortic valve replacement in Behcet's disease : surgical modification to prevent valve detachment. Eur J Cardiothorac Surg 2009 ; 36 : 771-772.
PubMed
9. Sakuma K, et al. : Cryopreserved aortic homograft replacement in 3 patients with noninfectious inflammatory vascular disease. Jpn J Thorac Cardiovasc Surg 2001 ; 49 : 652-655.
PubMed
10. Tanaka H, et al. : Reoperation for prosthesis dehiscence caused by aortitis. J Thorac Cardiovasc Surg 2011 ; 142 : 1274-1275.
PubMed
11. Hollander SA, et al. : Behcet's disease and heart transplantation : a word of caution. J Heart Lung Transplant 2010 ; 29 : 1306-1308.
PubMed
12. Spiliotopoulos K, et al. : Surgical management of a left anterior descending pseudoaneurysm related to Behcet's disease. Ann Thorac Surg 2011 ; 91 : 912-914.
PubMed
13. Emmungil H, et al. : A rare but serious manifestation of Behcet's disease : intracardiac thrombus in 22 patients. Clin Exp Rheumatol 2014 ; 32 (Suppl 84) : S87-92.
 
14. Ozturk C, et al. : Multiple pseudoaneurysms of aortic arch in a patient with Behcet's disease. Eur Heart J Cardiovasc Imaging 2014 ; 15 : 1028.
 
15. Lai YR, et al. : Bilateral pulmonary artery aneurysms, coronary artery aneurysm, and ventricular pseudoaneurysm in Behcet disease. Ann Vasc Surg 2014 ; 28 : 741.
 
16. Cantasdemir M, et al. : Emergency endovascular management of pulmonary artery aneurysms in Behcet's disease : report of two cases and a review of the literature. Cardiovasc Intervent Radiol 2002 ; 25 : 533-537.
 
17. Ozeren M, et al. : Reoperation results of arterial involvement in Behcet's disease. Eur J Vasc Endovasc Surg 2000 ; 20 : 512-519.
PubMed
18. Hosaka T, et al. : Long-term outcome after surgical treatment of arterial lesions in Behcet disease. J Vasc Surg 2005 ; 4 : 116-121.
 
19. Iscan ZH, et al. : Compelling nature of arterial manifestations in Behcet disease. J Vasc Surg. 2005 ; 41 : 53-58.
PubMed
20. Kalko Y, et al. : The surgical treatment of arterial aneurysms in Behcet disease : a report of 16 patients. J Vasc Surg 2005 ; 42 ; 673-677.
PubMed
21. Park MC, et al. : Surgical outcomes and risk factors for postoperative complications in patients with Behcet's disease. Clin Rheumatol 2007 ; 26 : 1475-1480.
PubMed
22. Alpagut U, et al. : Major arterial involvement and review of Behcet's disease. Ann Vasc Surg 2007 ; 21 : 232-239.
PubMed
23. Kwon TW, et al. : Surgical treatment result of abdominal aortic aneurysm in Behcet's disease. Eur J Vasc Endovasc Surg 2008 ; 35 : 173-180.
PubMed
24. Tuzun H, et al. : Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. J Vasc Surg 2012 ; 55 : 157-163.
PubMed
25. Saadoun OD, et al. : Long-term outcome of arterial lesions in Behcet disease : a series of 101 patients. Medicine (Baltimore) 2012 ; 91 : 18-24.
 
26. Ha YJ, et al. : Long-term clinical outcomes and risk factors for the occurrence of post-operative complications after cardiovascular surgery in patients with Behcet's disease. Clin Exp Rheumatol 2012 ; 30 (Suppl 72) : S18-26.
 
27. Hosaka A, et al. : Prognosis of arterial aneurysm after surgery in patients with Behcet's disease. Int Angiol 2014 ; 33 : 419-425.
PubMed
28. Liu CW, et al. : Endovascular treatment of aortic pseudoaneurysm in Behcet disease. J Vasc Surg 2009 ; 50 : 1025-1030.
PubMed
29. Kim WH, et al. : Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Behcet disease. J Endovasc Ther 2009 ; 16 : 631-636.
PubMed
30. Kim SW, et al. : Outcomes of endovascular treatment for aortic pseudoaneurysm in Behcet's disease. J Vasc Surg 2014 ; 59 : 608-614.
PubMed
31. Balcioglu O, et al. : Endovascular Repair and Adjunctive Immunosuppressive Therapy of Aortic Involvement in Behcet's Disease. Eur J Vasc Endovasc Surg 2015 ; 50 : 593-598.
PubMed
32. Liu Q, et al. : Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Behcet disease. Surgery 2016 ; 159 : 1422-1429.
PubMed
P.138 掲載の参考文献
1. Sato T, et al. : Urgent Surgical Management of Deep Femoral Artery Aneurysm in a Patient with Pre-Vasculo-Behcet Status. Ann Vasc Dis 2015 ; 8 : 116-119.
 
2. Maeda H, et al. : An impending rupture of a celiac artery aneurysm in a patient with Behcet's disease-extra-anatomic aorto-common hepatic artery bypass : report of a case. Surg Today 2008 ; 38 : 163-165.
 
3. Koksoy C, et al. : Surgical treatment of peripheral aneurysms in patients with Behcet's disease. Eur J Vasc Endovasc Surg 2011 ; 42 : 525-530.
PubMed
4. Kalko Y, et al. : The surgical treatment of arterial aneurysms in Behcet disease : a report of 16 patients. J Vasc Surg 2005 ; 42 : 673-677.
PubMed
5. Owlia MB, et al. : Behcet's Disease : New Concepts in Cardiovascular Involvements and Future Direction for Treatment. ISRN Pharmacol 2012 ; 2012 : 760484.
PubMed
6. 日本循環器学会, 他 : Behcet病. 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版). 2015 : 62-63.
 
7. Warrington KJ, et al. : Vasculitis and Other Arteriopathies. Behcet disease. In : Cronenwett JL, et al. (eds) : Rutherford's Vascular Surgery. 7th ed, Saunders, Philadelphia, 2010 : 1156-1168.
 
P.139 掲載の参考文献
1. Ozeren M, et al. : Reoperation results of arterial involvement in Behcet's disease. Eur J Vasc Endovasc Surg 2000 ; 20 : 512-519.
PubMed
1. Takeno M, et al. : Vascular Involvement of Behcet's disease. In : Ishigatsubo Y (eds) : Behcet's Disease. Springer Japan, 2015 : 79-100.
 
2. Kim SW, et al. : Outcomes of endovascular treatment for aortic pseudoaneurysm in Behcet's disease. J Vasc Surg 2014 ; 59 : 608-614.
PubMed
2. Hosaka A, et al. : Long-term outcome after surgical treatment of arterial lesions in Behcet disease. J Vasc Surg 2005 ; 42 : 116-121.
PubMed
3. Tsuda K, et al. : Endovascular Treatment of a Ruptured Innominate Artery Aneurysm in Behcet Disease. Ann Vasc Surg 2016 ; 33 : 230.
 
3. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
4. Liu CW, et al. : Endovascular treatment of aortic pseudoaneurysm in Behcet disease. J Vasc Surg 2009 ; 50 : 1025-1030.
PubMed
4. Le Thi Huong D, et al. : Arterial lesions in Behcet's disease. A study in 25 patients. J Rheumatol 1995 ; 22 : 2103-2113.
PubMed
5. Saadoun D, et al. : Long-term outcome of arterial lesions in Behcet disease : a series of 101 patients. Medicine (Baltimore) 2012 ; 91 : 18-24.
PubMed
5. Ulusan Z, et al. : Right common iliac artery stenosis and stent insertion in Behcet's disease. Cardiovasc J Afr 2011 ; 22 : e4-6.
PubMed
6. Kwon TW, et al. : Surgical treatment result of abdominal aortic aneurysm in Behcet's disease. Eur J Vasc Endovasc Surg 2008 ; 35 : 173-180.
PubMed
6. Park MC, et al. : Surgical outcomes and risk factors for postoperative complications in patients with Behcet's disease. Clin Rheumatol 2007 ; 26 : 1475-1480.
PubMed
P.140 掲載の参考文献
1. 廣畑俊成, 他 : 神経ベーチェット病の診療のガイドライン. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23～25年度総合研究報告書 (研究代表者 ; 石ヶ坪良明). 2014 : 247-252.
 
2. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
3. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
4. Hirohata S, et al. : Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 2015 ; 349 : 143-148.
PubMed
P.141 掲載の参考文献
1. Fujikawa K, et al. : Successful treatment of refractory neuro-Behcet's disease with infliximab : a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007 ; 66 : 136-137.
PubMed
1. 廣畑俊成, 他 : 神経ベーチェット病の診療のガイドライン. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23～25年度総合研究報告書 (研究代表者 ; 石ヶ坪良明). 2014 : 247-252.
 
2. Di Filippo M, et al. : Infliximab monotherapy for neuro-Behcet's disease : a case report. J Neurol Sci 2014 ; 347 : 389-390.
PubMed
2. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
3. Siva A, et al. : Behcet's Disease. Curr Treat Options Neurol 2000 ; 2 : 435-448.
PubMed
3. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
P.142 掲載の参考文献
1. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
1. Kotake S, et al. : Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999 ; 106 : 586-589.
PubMed
2. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
3. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
P.143 掲載の参考文献
1. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
P.144 掲載の参考文献
1. Hirohata S, et al. : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-965.
PubMed
2. Desbois AC, et al. : Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease : An Observational Study. Medicine (Baltimore) 2016 ; 95 : e3550.
 
3. Hibi T, et al. : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016 ; 95 : e3863.
 
4. Zeydan B, et al. : Infliximab is a plausible alternative for neurologic complications of Behcet disease. Neurol Neuroimmunol Neuroinflamm 2016 ; 3 : e258.
PubMed
P.145 掲載の参考文献
1. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
1. Hirohata S, et al. : Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997 ; 82 : 12-17.
PubMed
2. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
3. Hirohata S, et al. : Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998 ; 159 : 181-185.
PubMed
4. Kikuchi H, et al. : Low dose MTX for progressive neuro-Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003 ; 528 : 575-578.
PubMed
5. Kikuchi H, et al. : Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
P.146 掲載の参考文献
1. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
1. Hirohata S, et al. : Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998 ; 159 : 181-185.
PubMed
2. Hirohata S, et al. : Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997 ; 82 : 12-17.
PubMed
2. Kikuchi H, et al. : Low dose MTX for progressive neuro-Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003 ; 528 : 575-578.
PubMed
3. Kikuchi H, et al. : Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
P.147 掲載の参考文献
1. Kikuchi H, et al. : Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behcet's disease. J Neurol Sci 2014 ; 337 : 80-85.
PubMed
1. Hirohata S, et al. : Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 2015 ; 349 : 143-148.
PubMed
2. Kikuchi H, et al. : Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behcet's disease. J Neurol Sci 2014 ; 337 : 80-85.
PubMed
2. Hirohata S, et al. : Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 2015 ; 349 : 143-148.
PubMed
3. Hirohata S, et al. : Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998 ; 159 : 181-185.
PubMed
4. Kikuchi H, et al. : Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
P.148 掲載の参考文献
1. Mittal S, et al. : Behcet's Disease. In : Sawhney S, et al. (eds) : Pediatric Rheumatology. Springer, Singapore 2017 : 487-497.
 
2. 日本ベーチェット病学会 : ベーチェット病の診断基準 (2016年小改訂). 2016. http://www-user.yokohama-cu.ac.jp/~jbehcet/jigyou/shindan.html (アクセス日 : 2019年10月23日)
 
3. 山口賢一, 他 : 小児Behcet's病. 別冊日本臨床 2015 ; 34 : 867-873.
 
4. Kone-Paut I, et al. : Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease : an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 2011 ; 50 : 184-188.
PubMed
5. Paisal V, et al. : Childhood onset of behcet disease (BD) symptoms in an adult cohort of BD patients. http://dx.doi.org/10.1136/annrheumdis-2017-eular.6077 (アクセス日 : 2018年12月31日).
 
P.149 掲載の参考文献
1. Mittal S, et al. : Behcet's Disease. In : Sawhney S, et al. (eds) : Pediatric Rheumatology, Springer, Singapore 2017 : 487-497.
 
2. Ozen S : Behcet Disease. In : Petty RE, et al. (eds) : Textbook of Pediatric Rheumatology. 7th ed, Elsevier, 2016 : 526-532.
 
3. 日本ベーチェット病学会 : ベーチェット病の診断基準 (2016年小改訂). 2016. http://www-user.yokohama-cu.ac.jp/~jbehcetjigyou/shindan.html (アクセス日 : 2019年10月23日)
 
4. Kadowaki T, et al. : Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol 2018 ; 141 : 1485-1488.
PubMed
P.150 掲載の参考文献
1. Ozen S : Behcet Disease. In : Petty RE, et al. (eds) : Textbook of Pediatric Rheumatology. 7th ed, Elsevier, 2016 : 526-532.
 
2. Hatami G, et al. : EULAR recommendations for the management of Behcet's disease. Ann Rheum Dis 2008 ; 67 : 1656-1662.
 
3. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
4. Mittal S, et al. : Behcet's Disease. In : Sawhney S, et al. (eds) : Pediatric Rheumatology. Springer, Singapore, 2017 : 487-497.
 
5. インフリキシマブ添付文書. 日本標準商品分類番号 87239. 2019年5月改訂 (第1版).
 
6. ナプロキセン添付文書. 日本標準商品分類番号 871149. 2017年10月改訂 (第17版).
 
7. コルヒチン添付文書. 日本標準商品分類番号 873941. 2016年9月改訂 (第12版).
 
8. アザチオプリン添付文書. 日本標準商品分類番号 873999. 2019年2月改訂 (第17版).
 
9. アダリムマブ添付文書. 日本標準商品分類番号 873999. 2019年4月改訂 (第36版)
 
P.151 掲載の参考文献
1. 日本小児感染症学会 : 小児リウマチ性疾患患者に対する予防接種. 小児の臓器移植および免疫不全状態における予防接種ガイドライン 2014. 協和企画, 2014 : 77-85.
 
2. Heijstek MW, et al. : EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011 ; 70 : 1704-1712.
PubMed
3. van Assen S, et al. : EULAR recommendations for vaccination in adult patients with autoimmune Inflammatory rheumatic diseases. Ann Rheum Dis 2011 ; 70 : 414-422.
PubMed
4. Erkek E, et al. : Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol 2005 ; 20 : 1508-1511.
PubMed
5. Hugle T, et al. : Streptococcal hypersensitivity reloaded : severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology (Oxford) 2012 ; 51 : 761-762.
PubMed
6. Kawano Y, et al. : Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine 2015 ; 33 : 1440-1445.
PubMed
7. Shinjoh M, et al. : Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine 2015 ; 33 : 701-707.
PubMed
8. Kamei K, et al. : Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents. J Pediatr 2018 ; 196 : 217-222.
PubMed
P.152 掲載の参考文献
1. Royal College of Nursing : Adolescent Transitional Care ; RCN Guidance for Nursing Staff. https://scadmin.rcn.org.uk/-/media/royalcollege-of-nursing/documents/publications/2013/december/pub-004510.pdf (アクセス日 : 2018年12月31日)
 
2. Foster HE, et al. : EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis 2017 ; 76 : 639-646.
PubMed
3. 東野博彦 : 小児期発症の慢性疾患患児の長期支援について 小児-思春期-成人医療のギャップを埋める「移行プログラム」の作成をめざして. 小児内科 2006 ; 38 : 962-968.
 
4. 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性腎疾患に関する調査研究」研究班 診療ガイドライン分科会トランジションWG, 他 : 小児慢性腎臓病患者における移行医療についての提言-思春期・若年成人に適切な医療を提供するために-. https://www.jsn.or.jp/academicinfo/report.php (アクセス日 : 2018年12月31日)
 
石崎優子 (編) : 小児期発症慢性疾患患者のための移行支援ガイド. じほう, 2017.
 
P.157 掲載の参考文献
1. 日本リウマチ学会 : 関節リウマチ (RA) に対するTNF 阻害薬使用ガイドライン (2019年6月9日改訂版). 2019.
 
2. 日本眼炎症学会TNF阻害薬使用検討委員会 : 非感染性ぶどう膜炎に対するTNF阻害薬使用指針および安全対策マニュアル (2016年版).
Medical*Online
3. 日本呼吸器学会生物学的製剤と呼吸器疾患・診療の手引き作成委員会 : 生物学的製剤と呼吸器疾患 診療の手引き. 2014.
 
4. 日本肝臓学会 肝炎診療ガイドライン作成委員会 (編) : B型肝炎治療ガイドライン (第3.1版) 2019年3月. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b (アクセス日 : 2019年8月28日)
 
P.158 掲載の参考文献
1. 日本眼炎症学会TNF阻害薬使用検討委員会 : 非感染性ぶどう膜炎に対するTNF阻害薬使用指針および安全対策マニュアル (2016年版).
Medical*Online
2. 日本皮膚科学会 : 乾癬における生物学的製剤の使用ガイダンス (2018年版).
 
3. 日本リウマチ学会 : 関節リウマチ (RA) に対するTNF 阻害薬使用ガイドライン (2019年6月29日改訂版). 2019.
 
4. レ ミケード点滴静注用 100 特定使用成績調査 (ベーチェット病による難治性網膜ぶどう膜炎). (2017年6月13 日) https://rctportal.niph.go.jp/s/detail/um?trial_id=UMIN000027733 (アクセス日 : 2019年8月7日).
 
5. Lichtenstein GR, et al. : Drug therapies and the risk of malignancy in Crohn's disease : results from the TREAT(TM) Registry. Am J Gastroenterol 2014 ; 109 : 212-223.
 
6. Biancone L, et al. : Infliximab and newly diagnosed neoplasia in Crohn's disease : a multicentre matched pair study. Gut 2006 ; 55 : 228-233.
PubMed
7. Burmester GR, et al. : Adalimumab : long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013 ; 72 : 517-524.
PubMed
8. Dixon WG, et al. : Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy : results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010 ; 62 : 755-763.
 
9. Yates WB, et al. : Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy : a tertiary referral cohort study. Ophthalmology 2015 ; 122 : 265-273.
PubMed
10. Kempen JH, et al. : Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs : retrospective cohort study. BMJ 2009 ; 339 : b2480.
PubMed
11. FDA Drug Safety Communication : UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy. (02/13/2018). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-tumor-necrosis-factor-tnf-blockers-and-risk-pediatric (アクセス日 : 2019年8月7日)
 
12. Singh JA, et al. : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016 ; 68 : 1-26.
PubMed
P.159 掲載の参考文献
1. レミケード点滴静注用 100 特定使用成績調査 (ベーチェット病による難治性網膜ぶどう膜炎). (2017年6月13日) https://rctportal.niph.go.jp/s/detail/um?trial_id=UMIN000027733 (アクセス日 : 2019年8月7日).
 
2. 日本リウマチ学会 : 関節リウマチ (RA) に対するTNF阻害薬使用ガイドライン (2019年6月29日改訂版). 2019.
 
3. 日本呼吸器学会生物学的製剤と呼吸器疾患・診療の手引き作成委員会 : 生物学的製剤と呼吸器疾患 診療の手引き. 2014
 
P.160 掲載の参考文献
1. Ferreira I, et al. : Vaccines and biologics. Ann Rheum Dis 2014 ; 73 : 1446-1454.
PubMed
2. 日本リウマチ学会 : 関節リウマチ (RA) に対するTNF 阻害薬使用ガイドライン (2019年6月29日改訂版). 2019.
 
P.161 掲載の参考文献
1. Ingalls TH, et al. : Colchicine-induced craniofacial defects in the mouse embryo. Arch Environ Health 1968 ; 16 : 326-332.
PubMed
1. レミケード点滴静注用 100 関節リウマチ使用成績調査 (全例調査) 報告書 (田辺三菱製薬株式会社資料).
 
2. Koike T, et al. : Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of 7740 patients. Mod Rheumatol 2014 ; 24 : 390-398.
PubMed
2. Indraratna PL, et al. : Use of colchicine in pregnancy : a systematic review and meta-analysis. Rheumatology (Oxford) 2018 ; 57 : 382-387.
PubMed
3. Ozen S, et al. : EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016 ; 75 : 644-651.
PubMed
3. Ohno S, et al. : Efficacy, safety, and pharmacokinetics of mutiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-1368.
 
4. Gotestam Skorpen C, et al. : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 ; 75 : 795-810.
PubMed
4. レミケード点滴静注用 100 ベーチェット病による難治性網膜ブドウ膜炎適正使用情報 使用成績調査 (全例調査) の中間報告 (田辺三菱製薬株式会社資料).
 
5. Cottone M, et al. : Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011 ; 9 : 30-35.
PubMed
5. 審査報告書 (コルヒチン) 平成28年8月30日 独立行政法人医薬品医療機器総合機構.
 
6. Noel N, et al. : Behcet's disease and pregnancy. Arthritis Rheum 2013 ; 65 : 2450-2456.
PubMed
7. 日本産科婦人科学会, 他 : 産婦人科診療ガイドライン-産科編 2017. http://www.jsog.or.jp/activity/pdf/gl_sanka_2017.pdf (アクセス日 : 2019年8月7日)
 
P.162 掲載の参考文献
1. Mizushima Y, et al. : Colchicine in Behcet's disease. Lancet 1977 ; 2 : 1037.
PubMed
2. Sarica K, et al. : Urological evaluation of Behcet patients and the effect of colchicine on fertility. Eur Urol 1995 ; 27 : 39-42.
PubMed
3. Haimov-Kochman R, et al. : The effect of colchicine treatment on sperm production and function : a review. Hum Reprod 1998 ; 13 : 360-362.
PubMed
4. Uzunaslan D, et al. : No appreciable decrease in fertility in Behcet's syndrome. Rheumatology (Oxford) 2014 ; 53 : 828-833.
PubMed
5. Ozen S, et al. : EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016 ; 75 : 644-651.
PubMed
6. 吉田篤, 他 : ベーチェット病患者のコルヒチン治療と出産. 眼科 1985 ; 27 : 1359-1361.
 
7. 審査報告書 (コルヒチン) 平成28年8月30日 独立行政法人医薬品医療機器総合機構.
 
8. Ben-Chetrit E, et al. : Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine : is amniocentesis justified? Arthritis Care Res (Hoboken) 2010 ; 62 : 143-148.
PubMed
P.163 掲載の参考文献
1. Gotestam Skorpen C, et al. : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 ; 75 : 795-810.
PubMed
2. 齋藤滋, 他 : 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班 平成28年度～29年度総合研究報告書 (研究代表者 ; 齋藤滋). 2018 : 28-35.
 
3. Park-Wyllie L, et al. : Birth defects after maternal exposure to corticosteroids : prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000 ; 62 : 385-392.
PubMed
P.164 掲載の参考文献
1. Gotestam Skorpen C, et al. : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 ; 75 : 795-810.
PubMed
1. Gotestam Skorpen C, et al. : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 ; 75 : 795-810.
PubMed
2. Viktil KK, et al. : Outcomes after anti-rheumatic drug use before and during pregnancy : a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012 ; 41 : 196-201.
PubMed
2. Weber-Schoendorfer C, et al. : Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy : a prospective multicenter cohort study. Arthritis Rheumatol 2014 ; 66 : 1101-1110.
PubMed
3. Cleary BJ, et al. : Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res Clin Mol Teratol 2009 ; 85 : 647-654.
PubMed
3. Weber-Schoendorfer C, et al. : No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate : an observational cohort study. Rheumatology (Oxford) 2014 ; 53 : 757-763.
PubMed
4. Kirshon B, et al. : Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988 ; 72 : 462-464.
PubMed
4. Jharap B, et al. : Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014 ; 63 : 451-457.
PubMed
5. DeWitte DB, et al. : Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 1984 ; 105 : 625-628.
PubMed
5. Leyder M, et al. : Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy. Gynecol Obstet Invest 2011 ; 71 : 141-144.
PubMed
6. 齋藤滋, 他 : 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班 平成28年度～29年度総合研究報告書 (研究代表者 ; 齋藤滋). 2018 : 28-35.
 
6. 齋藤滋, 他 : 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班 平成28年度～29年度総合研究報告書 (研究代表者 ; 齋藤滋). 2018 : 28-35.
 
7. 日本産科婦人科学会, 他 : 産婦人科診療ガイドライン-産科編 2017. http://www.jsog.or.jp/activity/pdf/gl_sanka_2017.pdf (アクセス日 : 2018年8月7日)
 
P.165 掲載の参考文献
1. Mozaffari S, et al. : Pregnancy outcomes in women with inflammatory bowel diseases following exposure to thiopurines and antitumor necrosis factor drugs : a systematic review with meta-analysis. Hum Exp Toxicol 2015 ; 34 : 445-459.
PubMed
2. Julsgaard M, et al. : Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016 ; 151 : 110-119.
PubMed
3. van der Woude CJ, et al. : The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015 ; 9 : 107-124.
PubMed
4. Nguyen GC, et al. : The Toronto Consensus Statements for th Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology 2016 ; 150 : 734-757.
PubMed
5. Gotestam Skorpen C, et al. : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 ; 75 : 795-810.
PubMed
6. Takayama K, et al. : Successful treatment with infliximab for Behcet disease during pregnancy. Ocul Immunol Inflamm 2013 ; 21 : 321-323.
PubMed
7. Fujikawa K, et al. : Successful Treatment with Adalimumab for Intestinal Behcet's Disease during Pregnancy. Intern Med 2016 ; 55 : 1375-1378.
PubMed
P.166 掲載の参考文献
1. Gotestam Skorpen C, et al. : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 ; 75 : 795-810.
PubMed
1. Julsgaard M, et al. : Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016 ; 151 : 110-119.
PubMed
2. 齋藤滋, 他 : 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班 平成28年度～29年度総合研究報告書 (研究代表者 ; 齋藤滋). 2018 : 39-42.
 
2. Cheent K, et al. : Case Report : Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010 ; 4 : 603-605.
 
3. Julsgaard M, et al. : Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016 ; 151 : 110-119.
PubMed
3. van der Woude CJ, et al. : The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015 ; 9 : 107-124.
PubMed
4. 齋藤滋, 他 : 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班 平成28年度～29年度総合研究報告書 (研究代表者 ; 齋藤滋). 2018 : 36-38.
 
P.168 掲載の参考文献
1. Hatemi G, et al. : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 2018 ; 77 : 808-818.
PubMed
2. Yang SK, et al. : A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014 ; 46 : 1017-1020.
PubMed
3. Kakuta Y, et al. : NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J 2016 ; 16 : 280-285.
PubMed
4. Kakuta Y, et al. : NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol 2018 ; 53 : 1065-1078.
PubMed
5. 日本炎症性腸疾患学会 : 炎症性腸疾患患者に対するチオプリン製剤使用に関する通知 (NUDT15遺伝子多型判定キットの保険承認を受けて). http://www.jsibd.jp/office.html (アクセス日 : 2019年8月6日)
 

第5章 参考資料・情報

P.171 掲載の参考文献
1. International Study Group for Behcet's Disease : Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-1080.
 
2. Ideguchi H, et al. : Gastrointestinal manifestations of Behcet's disease in Japan : a study of 43 patients. Rheumatol Int 2014 ; 34 : 851-856.
PubMed
3. 桐野洋平, 他 : ベーチェット病特殊病型の診断の問題点. 590例の解析. 第60回日本リウマチ学会総会・学術集会抄録集. 2016 : 1-211.
 
4. International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD) : The International Criteria for Behcet's Disease (ICBD) : a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014 ; 28 : 338-347.
 
5. Kone-Paut I, et al. : Consensus classification criteria for paediatric Behcet's disease from a prospective observational cohort : PEDBD. Ann Rheum Dis 2016 ; 75 : 958-964.
PubMed
6. Kirino Y, et al. : Continuous evolution of clinical phenotype in 578 Japanese patients with Behcet's disease : a retrospective observational study. Arthritis Res Ther 2016 ; 18 : 217.
PubMed
P.173 掲載の参考文献
1. Kalra S, et al. : Diagnosis and management of Neuro-Behcet's disease : international consensus recommendations. J Neurol 2014 ; 261 : 1662-1676.
PubMed
2. Serdaroglu P : Behcet's disease and the nervous system. J Neurol 1998 ; 245 : 197-205.
PubMed
3. Al-Araji A, et al. : Neuro-Behcet's disease : epidemiology, clinical characteristics, and management. Lancet Neurol 2009 ; 8 : 192-204.
PubMed
4. Kidd D : The prevalence of Behcet's syndrome and its neurological complications in Hertfordshire, U.K. Adv Exp Med Biol. 2003 ; 528 : 95-97.
 
5. Akman-Demir G, et al. : Clinical patterns of neurological involvement in Behcet's disease : Evaluation of 200 patients. The Neuro-Behcet study Group Brain 1999 ; 122 : 2171-2181.
 
6. Siva A : Vasculitis of the nervous system. J Neurol 2001 ; 248 : 451-468.
PubMed
7. Ideguchi H, et al. : Neurological manifestations of Behcet's disease in Japan : A study of 54 patients. J Neurol 2010 ; 257 : 1012-1020.
PubMed
8. Hirohata S, et al. : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-413.
PubMed
9. Hirohata S, et al. : Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behcet's disease. Intern Med 2012 ; 51 : 3359-3365.
PubMed
10. Noel N, et al. : Long-term outcome of neuro-Behcet's disease. Arthritis Rheumatol 2014 ; 66 : 1306-1314.
PubMed
11. 黒原和博 : 神経ベーチェット病の副腎皮質ステロイド薬反応期および抵抗期の免疫学的検討. 臨床神経 1993 ; 33 : 455-458.
 
12. 広畑俊成 : 膠原病における中枢神経病変. 日本臨床 1999 ; 57 : 409-412.
Medical*Online
13. Akman-Demir G, et al. : Interleukin-6 in neuro-Behcet's disease : Association with disease subsets and long-term outcome. Cytokine 2008 ; 44 : 373-376.
PubMed
14. Coban O, et al. : Masked assessment of MRI findings : is it possible to differentiate neuro-Behcet's disease from other central nervous system. Neuroradiology 1999 ; 41 : 255-260.
PubMed
15. De Cata A, et al. : Prolonged remission of neuro-Behcet disease following autologous transplantation. Int J Immunopathol Pharmacol 2007 ; 20 : 91-96.
PubMed
16. Borhani Haghighi A, et al. : MRI findings of neuro-Behcet's disease. Clin Rheumatol 2011 ; 30 : 765-770.
PubMed
17. Kanoto M, et al. : Brain stem and cerebellar atrophy in chronic progressive neuro-Behcet's disease. Eur J Radiol 2013 ; 82 : 146-150.
PubMed
18. Matsui T, et al. : An attack of acute neuro-Behcet's disease during the course of chronic progressive neuro-Behcet's disease : report of two cases. Mod Rheumatol 2010 ; 20 : 621-626.
PubMed
19. Nakamura Y, et al. : Magnetic resonance imaging and brain-stem auditory evoked potentials in neuro-Behcet's disease. J Neurol 1994 ; 241 : 481-486.
PubMed
20. Sumita Y, et al. : Elevated BAFF levels in the cerebrospinal fluid of patients with neuro-Behcet's disease : BAFF is correlated with progressive dementia and psychosis. Scand J Immunol 2012 ; 75 : 633-640.
PubMed
21. International Study Group for Behcet's Disease : Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-1080.
 
22. Ishido M, et al. : Distinct clinical features between acute and chronic progressive parenchymal neuro-Behcet disease : meta-analysis. Sci Rep 2017 ; 7 : 10196.
PubMed

書評

最近チェックした商品履歴

Loading...